Regulation	O
of	O
the	O
human	B-DNA
MAT2B	I-DNA
gene	I-DNA
encoding	O
the	O
regulatory	B-protein
beta	I-protein
subunit	I-protein
of	O
methionine	B-protein
adenosyltransferase	I-protein
,	O
MAT	B-protein
II	I-protein
.	O

Methionine	B-protein
adenosyltransferase	I-protein
(	O
MAT	B-protein
)	O
catalyzes	O
the	O
biosynthesis	O
of	O
S-adenosylmethionine	B-protein
(	O
AdoMet	B-protein
)	O
,	O
a	O
key	O
molecule	O
in	O
transmethylation	O
reactions	O
and	O
polyamine	O
biosynthesis	O
.	O

The	O
MAT	B-protein
II	I-protein
isozyme	I-protein
consists	O
of	O
a	O
catalytic	B-protein
alpha2	I-protein
and	I-protein
a	I-protein
regulatory	I-protein
beta	I-protein
subunit	I-protein
.	O

Down-regulation	O
of	O
the	O
MAT	B-protein
II	I-protein
beta	I-protein
subunit	I-protein
expression	O
causes	O
a	O
6-10-fold	O
increase	O
in	O
intracellular	O
AdoMet	B-protein
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
the	O
beta	B-protein
subunit	I-protein
expression	O
is	O
regulated	O
,	O
we	O
cloned	O
the	O
MAT2B	B-DNA
gene	I-DNA
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
5'-flanking	B-DNA
sequences	I-DNA
,	O
and	O
elucidated	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
regulation	O
of	O
its	O
promoter	B-DNA
.	O

Transcription	O
of	O
the	O
MAT2B	B-DNA
gene	I-DNA
initiates	O
at	O
position	O
-203	O
relative	O
to	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
.	O

Promoter	B-DNA
deletion	I-DNA
analysis	I-DNA
defined	O
a	O
minimal	B-DNA
promoter	I-DNA
between	O
positions	B-DNA
+52	I-DNA
and	I-DNA
+93	I-DNA
base	O
pairs	O
,	O
a	O
GC-rich	B-DNA
region	I-DNA
.	O

Inclusion	O
of	O
the	O
sequences	O
between	O
-4	O
and	O
+52	O
enhanced	O
promoter	O
activity	O
;	O
this	O
was	O
primarily	O
because	O
of	O
an	O
Sp1	B-DNA
recognition	I-DNA
site	I-DNA
at	O
+9/+15	O
.	O

The	O
inclusion	O
of	O
sequences	O
up	O
to	O
position	O
-115	O
provided	O
full	O
activity	O
;	O
this	O
was	O
attributed	O
to	O
a	O
TATA	B-DNA
at	O
-32	O
.	O

The	O
Sp1	B-DNA
site	I-DNA
at	O
position	O
+9	O
was	O
key	O
for	O
the	O
formation	O
of	O
protein.DNA	O
complexes	O
.	O

Mutation	O
of	O
both	O
the	O
Sp1	B-DNA
site	I-DNA
at	O
+9	O
and	O
the	O
TATA	B-DNA
at	O
-32	O
reduced	O
promoter	O
activity	O
to	O
its	O
minimal	O
level	O
.	O

Supershift	O
assays	O
showed	O
no	O
effect	O
of	O
the	O
anti-Sp1	B-protein
antibody	I-protein
on	O
complex	O
formation	O
,	O
whereas	O
the	O
anti-Sp3	B-protein
antibody	I-protein
had	O
a	O
strong	O
effect	O
on	O
protein.DNA	O
complex	O
formation	O
,	O
suggesting	O
that	O
Sp3	B-protein
is	O
one	O
of	O
the	O
main	O
factors	O
binding	O
to	O
this	O
Sp1	B-DNA
site	I-DNA
.	O

Chromatin	O
immunoprecipitation	O
assays	O
supported	O
the	O
involvement	O
of	O
both	O
Sp1	B-protein
and	O
Sp3	B-protein
in	O
complexes	O
formed	O
on	O
the	O
MAT2B	B-DNA
promoter	I-DNA
.	O

The	O
data	O
show	O
that	O
the	O
5'-untranslated	B-DNA
sequences	I-DNA
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
MAT2B	B-DNA
gene	I-DNA
and	O
identifies	O
the	O
Sp1	B-DNA
site	I-DNA
at	O
+9	O
as	O
a	O
potential	O
target	O
for	O
modulating	O
MAT2B	O
expression	O
,	O
a	O
process	O
that	O
can	O
have	O
a	O
major	O
effect	O
on	O
intracellular	O
AdoMet	B-protein
levels	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

276	NULL
,	NULL
No	NULL
.	NULL

27	NULL
,	NULL
Issue	NULL
of	NULL
July	NULL
6	NULL
,	NULL
pp	NULL
.	NULL

24918-24924	NULL
,	NULL
2001	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Regulation	NULL
of	NULL
the	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
Encoding	NULL
the	NULL
Regulatory	NULL
B	NULL
Subunit	NULL
of	NULL
Methionine	NULL
Adenosyltransferase	NULL
,	NULL
MAT	NULL
II*	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
March	NULL
29	NULL
,	NULL
2001	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
May	NULL
1	NULL
,	NULL
2001	NULL
Published	NULL
,	NULL
JBC	NULL
Papers	NULL
in	NULL
Press	NULL
,	NULL
May	NULL
3	NULL
,	NULL
2001	NULL
,	NULL
DOI	NULL
10.1074/jbe.M102816200	NULL
Leighton	NULL
LeGros	NULL
#	NULL
§T|	NULL
,	NULL
Abdel-Baset	NULL
Halim	NULL
#	NULL
§1	NULL
]	NULL
|	NULL
,	NULL
Margaret	NULL
E.	NULL
Chamberlin	NULL
$	NULL
§	NULL
,	NULL
Arthur	NULL
Geller**	NULL
,	NULL
and	NULL
Malak	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
{	NULL
Surgery	NULL
,	NULL
**Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
and	NULL
Biochemistry	NULL
,	NULL
University	NULL
of	NULL
Tennessee	NULL
,	NULL
Memphis	NULL
,	NULL
Tennessee	NULL
38163	NULL
and	NULL
the	NULL
§Veterans	NULL
Affairs	NULL
Medical	NULL
Center	NULL
,	NULL
Memphis	NULL
,	NULL
Tennessee	NULL
38104	NULL
Methionine	NULL
adenosyltransferase	NULL
(	NULL
MAT	NULL
)	NULL
catalyzes	NULL
the	NULL
biosynthesis	NULL
of	NULL
S-adenosylmethionine	NULL
(	NULL
AdoMet	NULL
)	NULL
,	NULL
a	NULL
key	NULL
molecule	NULL
in	NULL
transmethylation	NULL
reactions	NULL
and	NULL
polyamine	NULL
biosynthesis	NULL
.	NULL

The	NULL
MAT	NULL
II	NULL
isozyme	NULL
consists	NULL
of	NULL
a	NULL
catalytic	NULL
«	NULL
2	NULL
and	NULL
a	NULL
regulatory	NULL
B	NULL
subunit	NULL
.	NULL

Down-regulation	NULL
of	NULL
the	NULL
MAT	NULL
II	NULL
B	NULL
subunit	NULL
expression	NULL
causes	NULL
a	NULL
6-10-fold	NULL
increase	NULL
in	NULL
intracellular	NULL
AdoMet	NULL
levels	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
B	NULL
subunit	NULL
expression	NULL
is	NULL
regulated	NULL
,	NULL
we	NULL
cloned	NULL
the	NULL
MAT2B	NULL
gene	NULL
,	NULL
determined	NULL
its	NULL
organization	NULL
,	NULL
characterized	NULL
its	NULL
5'-flanking	NULL
sequences	NULL
,	NULL
and	NULL
elucidated	NULL
the	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
regulation	NULL
of	NULL
its	NULL
promoter	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
initiates	NULL
at	NULL
position	NULL
-203	NULL
relative	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

Promoter	NULL
deletion	NULL
analysis	NULL
defined	NULL
a	NULL
minimal	NULL
promoter	NULL
between	NULL
positions	NULL
+52	NULL
and	NULL
+93	NULL
base	NULL
pairs	NULL
,	NULL
a	NULL
GC-rich	NULL
region	NULL
.	NULL

Inclusion	NULL
of	NULL
the	NULL
sequences	NULL
between	NULL
-4	NULL
and	NULL
+52	NULL
enhanced	NULL
promoter	NULL
activity	NULL
;	NULL
this	NULL
was	NULL
primarily	NULL
because	NULL
of	NULL
an	NULL
Spl	NULL
recognition	NULL
site	NULL
at	NULL
+9/+15	NULL
.	NULL

The	NULL
inclusion	NULL
of	NULL
sequences	NULL
up	NULL
to	NULL
position	NULL
-115	NULL
provided	NULL
full	NULL
activity	NULL
;	NULL
this	NULL
was	NULL
attributed	NULL
to	NULL
a	NULL
TATA	NULL
at	NULL
-32	NULL
.	NULL

The	NULL
Spl	NULL
site	NULL
at	NULL
position	NULL
+9	NULL
was	NULL
key	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

Mutation	NULL
of	NULL
both	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9	NULL
and	NULL
the	NULL
TATA	NULL
at	NULL
-32	NULL
reduced	NULL
promoter	NULL
activity	NULL
to	NULL
its	NULL
minimal	NULL
level	NULL
.	NULL

Supershift	NULL
assays	NULL
showed	NULL
no	NULL
effect	NULL
of	NULL
the	NULL
anti-Spl	NULL
antibody	NULL
on	NULL
complex	NULL
formation	NULL
,	NULL
whereas	NULL
the	NULL
anti-Sp3	NULL
antibody	NULL
had	NULL
a	NULL
strong	NULL
effect	NULL
on	NULL
protein-DNA	NULL
complex	NULL
formation	NULL
,	NULL
suggesting	NULL
that	NULL
Sp3	NULL
is	NULL
one	NULL
of	NULL
the	NULL
main	NULL
factors	NULL
binding	NULL
to	NULL
this	NULL
Spl	NULL
site	NULL
.	NULL

Chromatin	NULL
immunoprecipitation	NULL
assays	NULL
supported	NULL
the	NULL
involvement	NULL
of	NULL
both	NULL
Spl	NULL
and	NULL
Sp3	NULL
in	NULL
complexes	NULL
formed	NULL
on	NULL
the	NULL
MAT2B	NULL
promoter	NULL
.	NULL

The	NULL
data	NULL
show	NULL
that	NULL
the	NULL
-untranslated	NULL
sequences	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
MAT2B	NULL
gene	NULL
and	NULL
identifies	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9	NULL
as	NULL
a	NULL
potential	NULL
target	NULL
for	NULL
modulating	NULL
MAT2B	NULL
expression	NULL
,	NULL
a	NULL
process	NULL
that	NULL
can	NULL
have	NULL
a	NULL
major	NULL
effect	NULL
on	NULL
intracellular	NULL
AdoMet	NULL
levels	NULL
.	NULL

Methionine	NULL
adenosyltransferase	NULL
(	NULL
MAT	NULL
)	NULL
(	NULL
ATP-1-methionine	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
GM-54892-09	NULL
and	NULL
Merit	NULL
Review	NULL
Award	NULL
funds	NULL
from	NULL
Veterans	NULL
Affairs	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
(	NULL
s	NULL
)	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
has	NULL
been	NULL
submitted	NULL
to	NULL
the	NULL
GenBank	NULL
``	NULL
/	NULL
EBI	NULL
Data	NULL
Bank	NULL
with	NULL
accession	NULL
number	NULL
(	NULL
s	NULL
)	NULL
AYO33822	NULL
.	NULL

|	NULL
Both	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

7+	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
University	NULL
of	NULL
Tennessee	NULL
,	NULL
956	NULL
Court	NULL
Ave.	NULL
,	NULL
Suite	NULL
A-202	NULL
,	NULL
Memphis	NULL
,	NULL
TN	NULL
38163	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
901-448-7247	NULL
;	NULL
Fax	NULL
:	NULL
901-448-7208	NULL
;	NULL
E-mail	NULL
:	NULL
Mkotb	NULL
@	NULL
utmem.edu	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
MAT	NULL
,	NULL
methionine	NULL
adenosyltransferase	NULL
;	NULL
AdoMet	NULL
,	NULL
S-adenosylmethionine	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
kbp	NULL
,	NULL
kilobase	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
Ab	NULL
,	NULL
antibody	NULL
;	NULL
Pipes	NULL
,	NULL
1	NULL
,	NULL
4-piperazinediethanesulfonic	NULL
acid	NULL
;	NULL
LUC	NULL
,	NULL
luciferase	NULL
.	NULL

24918	NULL
S-adenosyltransferase	NULL
)	NULL
(	NULL
EC	NULL
2.5.1.6	NULL
)	NULL
catalyzes	NULL
the	NULL
biosynthesis	NULL
of	NULL
S-adenosylmethionine	NULL
(	NULL
AdoMet	NULL
)	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

AdoMet	NULL
is	NULL
the	NULL
major	NULL
methyl	NULL
donor	NULL
in	NULL
transmethylation	NULL
reactions	NULL
and	NULL
the	NULL
propyla-mine	NULL
donor	NULL
in	NULL
the	NULL
biosynthesis	NULL
of	NULL
polyamines	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

Further-more	NULL
,	NULL
AdoMet	NULL
participates	NULL
as	NULL
a	NULL
co-factor	NULL
in	NULL
key	NULL
metabolic	NULL
pathways	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

Most	NULL
species	NULL
studied	NULL
to	NULL
date	NULL
have	NULL
more	NULL
than	NULL
one	NULL
MAT	NULL
isozyme	NULL
(	NULL
6	NULL
)	NULL
.	NULL

In	NULL
mammals	NULL
,	NULL
the	NULL
two	NULL
major	NULL
MAT	NULL
isozymes	NULL
are	NULL
designated	NULL
MAT	NULL
IIII	NULL
and	NULL
MAT	NULL
II	NULL
(	NULL
7-10	NULL
)	NULL
.	NULL

The	NULL
MAT	NULL
III	NULL
isozymes	NULL
are	NULL
,	NULL
respectively	NULL
,	NULL
a	NULL
tetramer	NULL
and	NULL
dimer	NULL
of	NULL
a	NULL
catalytic	NULL
al	NULL
subunit	NULL
that	NULL
is	NULL
expressed	NULL
only	NULL
in	NULL
liver	NULL
(	NULL
7	NULL
,	NULL
11-13	NULL
)	NULL
.	NULL

The	NULL
MAT	NULL
II	NULL
isozyme	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
tissues	NULL
including	NULL
the	NULL
liver	NULL
(	NULL
9	NULL
,	NULL
14-21	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
from	NULL
our	NULL
group	NULL
(	NULL
15	NULL
,	NULL
22	NULL
)	NULL
have	NULL
determined	NULL
that	NULL
MAT	NULL
II	NULL
from	NULL
human	NULL
leukemic	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
from	NULL
activated	NULL
human	NULL
lymphocytes	NULL
,	NULL
is	NULL
a	NULL
hetero-oligomer	NULL
that	NULL
consists	NULL
of	NULL
«	NULL
2	NULL
(	NULL
53	NULL
kDa	NULL
)	NULL
,	NULL
«	NULL
2	NULL
'	NULL
(	NULL
51	NULL
kDa	NULL
)	NULL
,	NULL
and	NULL
B	NULL
(	NULL
38	NULL
kDa	NULL
)	NULL
subunits	NULL
.	NULL

The	NULL
«	NULL
2/B	NULL
hetero-oligomeric	NULL
composition	NULL
of	NULL
MAT	NULL
II	NULL
was	NULL
also	NULL
determined	NULL
in	NULL
bovine	NULL
brain	NULL
,	NULL
Ehrlich	NULL
ascites	NULL
tumor	NULL
,	NULL
and	NULL
calf	NULL
thymus	NULL
(	NULL
15	NULL
,	NULL
19	NULL
)	NULL
.	NULL

The	NULL
«	NULL
2	NULL
subunit	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
enzyme	NULL
catalytic	NULL
activity	NULL
and	NULL
is	NULL
post-translationally	NULL
modified	NULL
to	NULL
generate	NULL
a2	NULL
'	NULL
(	NULL
15	NULL
,	NULL
22-26	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Halim	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
reported	NULL
the	NULL
characterization	NULL
and	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
MAT2A	NULL
gene	NULL
and	NULL
found	NULL
it	NULL
to	NULL
be	NULL
remarkably	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
rat	NULL
and	NULL
mouse	NULL
MAT2A	NULL
genes	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
as	NULL
well	NULL
as	NULL
to	NULL
the	NULL
human	NULL
MATIA	NULL
gene	NULL
(	NULL
30	NULL
)	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
liver-specific	NULL
al	NULL
subunit	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
MAT	NULL
a	NULL
subunits	NULL
,	NULL
which	NULL
are	NULL
highly	NULL
conserved	NULL
throughout	NULL
evolution	NULL
,	NULL
the	NULL
subunit	NULL
of	NULL
MAT	NULL
II	NULL
seems	NULL
to	NULL
be	NULL
only	NULL
present	NULL
in	NULL
the	NULL
mammalian	NULL
species	NULL
(	NULL
15	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
cloned	NULL
and	NULL
characterized	NULL
the	NULL
human	NULL
MAT	NULL
II	NULL
8	NULL
subunit	NULL
(	NULL
26	NULL
,	NULL
31	NULL
)	NULL
,	NULL
found	NULL
that	NULL
it	NULL
has	NULL
no	NULL
catalytic	NULL
activity	NULL
,	NULL
and	NULL
confirmed	NULL
that	NULL
it	NULL
acts	NULL
as	NULL
a	NULL
regulatory	NULL
subunit	NULL
for	NULL
the	NULL
enzyme	NULL
.	NULL

When	NULL
$	NULL
3	NULL
associates	NULL
with	NULL
the	NULL
a	NULL
subunit	NULL
it	NULL
alters	NULL
its	NULL
kinetic	NULL
properties	NULL
and	NULL
renders	NULL
MAT	NULL
II	NULL
more	NULL
susceptible	NULL
to	NULL
product	NULL
inhibition	NULL
by	NULL
AdoMet	NULL
(	NULL
26	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
human	NULL
$	NULL
subunit	NULL
can	NULL
also	NULL
interact	NULL
with	NULL
the	NULL
al	NULL
subunit	NULL
of	NULL
MAT	NULL
IIII	NULL
and	NULL
the	NULL
Escherichia	NULL
coli	NULL
«	NULL
a	NULL
MAT	NULL
subunit	NULL
and	NULL
alter	NULL
their	NULL
kinetic	NULL
properties	NULL
as	NULL
well	NULL
(	NULL
26	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
MAT	NULL
II	NULL
«	NULL
2	NULL
,	NULL
«	NULL
2	NULL
'	NULL
,	NULL
and	NULL
B	NULL
subunits	NULL
varies	NULL
considerably	NULL
in	NULL
different	NULL
tissues	NULL
.	NULL

The	NULL
«	NULL
2	NULL
,	NULL
«	NULL
2	NULL
'	NULL
,	NULL
and	NULL
B	NULL
subunits	NULL
are	NULL
constitutively	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
leukemic	NULL
cells	NULL
and	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
normal	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

Stimulation	NULL
of	NULL
normal	NULL
human	NULL
lymphocytes	NULL
results	NULL
in	NULL
marked	NULL
changes	NULL
in	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
these	NULL
subunits	NULL
.	NULL

Nonphysiological	NULL
polyclonal	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
induces	NULL
an	NULL
increased	NULL
expression	NULL
of	NULL
the	NULL
«	NULL
2/a2	NULL
'	NULL
subunits	NULL
but	NULL
not	NULL
the	NULL
B	NULL
subunits	NULL
(	NULL
22	NULL
,	NULL
25	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
physiological	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
bacterial	NULL
superantigens	NULL
induces	NULL
an	NULL
up-regulation	NULL
of	NULL
the	NULL
«	NULL
2/a2	NULL
'	NULL
subunits	NULL
and	NULL
a	NULL
down-regulation	NULL
of	NULL
the	NULL
B	NULL
subunit	NULL
(	NULL
25	NULL
)	NULL
.	NULL

This	NULL
results	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
«	NULL
2	NULL
and	NULL
«	NULL
2	NULL
'	NULL
homo-	NULL
and/or	NULL
hetero-oligomers	NULL
(	NULL
no	NULL
B	NULL
)	NULL
with	NULL
a	NULL
3-fold	NULL
higher	NULL
K	NULL
,	NULL
,	NULL
,	NULL
for	NULL
L-Met	NULL
.	NULL

The	NULL
form	NULL
of	NULL
MAT	NULL
II	NULL
without	NULL
B	NULL
is	NULL
resistant	NULL
to	NULL
product	NULL
inhibition	NULL
by	NULL
AdoMet	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
form	NULL
of	NULL
MAT	NULL
II	NULL
found	NULL
in	NULL
resting	NULL
or	NULL
leukemic	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
TaBLE	NULL
I	NULL
Sequence	NULL
of	NULL
primers	NULL
used	NULL
for	NULL
MAT2B	NULL
promoter	NULL
constructs	NULL
Name	NULL
Primer	NULL
(	NULL
5'-3	NULL
'	NULL
)	NULL
Position	NULL
5'WP	NULL
ACTCGAGCTGCTTAGTCTTTAGTTT	NULL
-998	NULL
3'WP	NULL
GAAGCTTGCCCGCCGTCTTCAC	NULL
+204	NULL
5'BP1	NULL
ACTCGAGTGCCAGGGTTTACTTTCT	NULL
-826	NULL
5'BP2	NULL
GCTCGAGTGGGCTTGATTCTGGTTA	NULL
-596	NULL
5'BP3	NULL
TCTCGAGTTCATCTTCCTTCCCCTAC	NULL
-484	NULL
5'BPA4	NULL
ACTCGAGACGCCAACCCTTTTAT	NULL
-363	NULL
5'BP5	NULL
TCTCGAGCTTTTTATTCCACTTTTTAT	NULL
-287	NULL
5'BP6	NULL
ACTCGAGAAACTCAAGGCGATCCACTT	NULL
-174	NULL
3'BP6	NULL
TCTGCCCCCAGCCCAG	NULL
-2	NULL
5'BP	NULL
?	NULL

7	NULL
ACTCGAGAATAAAAAGCACTCAAATAAAATCTCC	NULL
-115	NULL
5'BP8	NULL
CCTCGAGACCGCGCGTACC	NULL
-4	NULL
3'BP8	NULL
GTTGATTGGCCACGCTCC	NULL
+51	NULL
5'BP9	NULL
ACTCGAGGGCGCGGCTATGGCAG	NULL
+52	NULL
5'BP10	NULL
TCTCGAGTCGTTCTGGGCCTAGGG	NULL
+98	NULL
5'BP11	NULL
ACTCGAGGGTTGGAGGAGGTGGCG	NULL
+154	NULL
T	NULL
cells	NULL
(	NULL
includes	NULL
$	NULL
)	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
the	NULL
down-regulation	NULL
of	NULL
the	NULL
subunit	NULL
in	NULL
physiologically	NULL
stimulated	NULL
T	NULL
cells	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
6-10-fold	NULL
increase	NULL
in	NULL
intracellular	NULL
AdoMet	NULL
levels	NULL
,	NULL
presumably	NULL
caused	NULL
by	NULL
the	NULL
loss	NULL
of	NULL
product	NULL
inhibition	NULL
of	NULL
the	NULL
enzyme	NULL
(	NULL
25	NULL
)	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
AdoMet	NULL
levels	NULL
is	NULL
likely	NULL
to	NULL
stimulate	NULL
certain	NULL
transmethylation	NULL
reactions	NULL
catalyzed	NULL
by	NULL
methyltrans-ferases	NULL
with	NULL
a	NULL
relatively	NULL
high	NULL
K	NULL
,	NULL
,	NULL
,	NULL
value	NULL
for	NULL
AdoMet	NULL
.	NULL

Based	NULL
on	NULL
our	NULL
previous	NULL
results	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
the	NULL
down-regulation	NULL
of	NULL
the	NULL
MAT	NULL
II	NULL
3	NULL
subunit	NULL
may	NULL
be	NULL
an	NULL
important	NULL
event	NULL
in	NULL
the	NULL
physiological	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
we	NULL
sought	NULL
to	NULL
characterize	NULL
the	NULL
regulation	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
the	NULL
chromosomal	NULL
localization	NULL
and	NULL
organization	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
and	NULL
provide	NULL
a	NULL
detailed	NULL
characterization	NULL
of	NULL
the	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
its	NULL
promoter	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Isolation	NULL
and	NULL
Genomic	NULL
Organization	NULL
of	NULL
the	NULL
MAT2B	NULL
Gene-Based	NULL
on	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
previously	NULL
reported	NULL
MAT	NULL
II	NULL
subunit	NULL
cDNA	NULL
(	NULL
31	NULL
)	NULL
,	NULL
forward	NULL
and	NULL
reverse	NULL
primers	NULL
spanning	NULL
the	NULL
entire	NULL
open	NULL
reading	NULL
frame	NULL
were	NULL
designed	NULL
and	NULL
used	NULL
to	NULL
amplify	NULL
genomic	NULL
DNA	NULL
isolated	NULL
from	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

Reactions	NULL
yielding	NULL
larger	NULL
than	NULL
expected	NULL
products	NULL
suggested	NULL
the	NULL
presence	NULL
of	NULL
introns	NULL
,	NULL
and	NULL
these	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
to	NULL
verify	NULL
the	NULL
authenticity	NULL
of	NULL
introns	NULL
.	NULL

Sequences	NULL
at	NULL
the	NULL
intron-exon	NULL
boundaries	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
were	NULL
determined	NULL
by	NULL
aligning	NULL
the	NULL
cDNA	NULL
sequence	NULL
of	NULL
MAT2B	NULL
cDNA	NULL
with	NULL
the	NULL
genomic	NULL
sequence	NULL
.	NULL

A	NULL
set	NULL
of	NULL
primers	NULL
,	NULL
GSF	NULL
(	NULL
5'-GATTCCTGAGTCCTGTCTTAG	NULL
)	NULL
and	NULL
GSR	NULL
(	NULL
5'-GCACTTTTGGCTTTCACTCAG	NULL
)	NULL
,	NULL
that	NULL
amplified	NULL
a	NULL
79-bp	NULL
product	NULL
that	NULL
included	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
intron	NULL
4	NULL
and	NULL
the	NULL
5	NULL
end	NULL
of	NULL
exon	NULL
5	NULL
were	NULL
used	NULL
to	NULL
screen	NULL
a	NULL
human	NULL
P1	NULL
genomic	NULL
library	NULL
(	NULL
Genome	NULL
Systems	NULL
,	NULL
Inc.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Positive	NULL
clones	NULL
were	NULL
partially	NULL
sequenced	NULL
to	NULL
ascertain	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
.	NULL

Clone	NULL
22646	NULL
was	NULL
selected	NULL
for	NULL
further	NULL
characterization	NULL
and	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
chromosomal	NULL
location	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
,	NULL
determine	NULL
gene	NULL
organization	NULL
,	NULL
verify	NULL
intron	NULL
positions	NULL
,	NULL
and	NULL
characterize	NULL
MAT2B	NULL
promoter	NULL
function	NULL
.	NULL

Chromosomal	NULL
Localization	NULL
of	NULL
the	NULL
Human	NULL
MAT2B	NULL
Subunit	NULL
Gene-Highly	NULL
purified	NULL
DNA	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
MAT2B	NULL
PL	NULL
genomic	NULL
clone	NULL
22646	NULL
using	NULL
the	NULL
Wizard	NULL
PureFection	NULL
DNA	NULL
purification	NULL
system	NULL
(	NULL
Pro-mega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
labeled	NULL
with	NULL
digoxigenin	NULL
dUTP	NULL
by	NULL
nick	NULL
translation	NULL
combined	NULL
with	NULL
sheared	NULL
human	NULL
DNA	NULL
and	NULL
hybridized	NULL
to	NULL
normal	NULL
metaphase	NULL
chromosomes	NULL
derived	NULL
from	NULL
phytohemagglutinin-stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
10	NULL
%	NULL
dextran	NULL
sulfate	NULL
,	NULL
and	NULL
2X	NULL
SSC	NULL
.	NULL

Specific	NULL
hybridization	NULL
signals	NULL
were	NULL
detected	NULL
by	NULL
using	NULL
fluorescein-conjugated	NULL
antidigoxigenin	NULL
antibodies	NULL
.	NULL

The	NULL
chromosomes	NULL
were	NULL
counterstained	NULL
with	NULL
propidium	NULL
io-dide	NULL
and	NULL
analyzed	NULL
.	NULL

Mapping	NULL
the	NULL
MAT2B	NULL
Gene	NULL
Transcription	NULL
Start	NULL
Site-Identification	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
was	NULL
done	NULL
by	NULL
primer	NULL
extension	NULL
analysis	NULL
using	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
prepared	NULL
from	NULL
normal	NULL
human	NULL
lymphocytes	NULL
.	NULL

The	NULL
primer	NULL
extension	NULL
reaction	NULL
was	NULL
conducted	NULL
using	NULL
the	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
primer	NULL
extension	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
500	NULL
ml	NULL
of	NULL
human	NULL
blood	NULL
by	NULL
the	NULL
Poly	NULL
(	NULL
A	NULL
)	NULL
Tract	NULL
mRNA	NULL
isolation	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Two	NULL
primers	NULL
,	NULL
Bral	NULL
5'-GTTCTT-TCTCCCTCCCCACCAT-3	NULL
'	NULL
(	NULL
complementary	NULL
to	NULL
positions	NULL
+22-+1	NULL
of	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
)	NULL
and	NULL
Bra2	NULL
5-CAGTTCTTTCTCCCTCCCCACC-3	NULL
'	NULL
(	NULL
complementary	NULL
to	NULL
positions	NULL
+24-+3	NULL
of	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
)	NULL
,	NULL
were	NULL
Human	NULL
Lymphocyte	NULL
MAT2B	NULL
Gene	NULL
Exon	NULL
:	NULL
1	NULL
2	NULL
34	NULL
5	NULL
6	NULL
7	NULL
a	NULL
10	NULL
A4	NULL
r	NULL
x	NULL
e	NULL
non	NULL
qi	NULL
A	NULL
poy	NULL
{	NULL
*A	NULL
~	NULL
2	NULL
``	NULL
moa	NULL
dab	NULL
\	NULL
a	NULL
%	NULL
*X	NULL
*~	NULL
4*	NULL
450	NULL
a	NULL
bon	NULL
ob	NULL
A\	NULL
As	NULL
~~	NULL
,	NULL
+	NULL
550	NULL
ad	NULL
an	NULL
Ga	NULL
o	NULL
C	NULL
Cp	NULL
``	NULL
ay	NULL
£	NULL
F4	NULL
y__1	NULL
N	NULL
c	NULL
&	NULL
[	NULL
_	NULL
zos	NULL
[	NULL
és	NULL
]	NULL
iso	NULL
[	NULL
us|	NULL
iss	NULL
|	NULL
is4	NULL
|1n4	NULL
]	NULL
|	NULL
171	NULL
|	NULL
sor	NULL
ﬂ	NULL
ATG	NULL
TAG	NULL
Exons	NULL
and	NULL
Introns	NULL
Exon	NULL
Intron	NULL
5	NULL
;	NULL
Amino	NULL
Acid	NULL
Number	NULL
Size	NULL
(	NULL
bp	NULL
)	NULL
Number	NULL
-	NULL
~Size	NULL
(	NULL
bp	NULL
)	NULL
lnlerrupiéd	NULL
Type	NULL
1	NULL
5NC	NULL
(	NULL
205	NULL
)	NULL
+	NULL
63	NULL
I	NULL
619	NULL
Glw/Glu22	NULL
0	NULL
2	NULL
189	NULL
II	NULL
1068	NULL
Gin/Pro8S	NULL
0	NULL
3	NULL
115	NULL
H	NULL
155	NULL
Alal23	NULL
I	NULL
4	NULL
153	NULL
IV	NULL
1730	NULL
Gly174	NULL
I	NULL
5	NULL
194	NULL
v	NULL
753	NULL
Lew/Asp239	NULL
0	NULL
6	NULL
114	NULL
VI	NULL
437	NULL
Pro/Mle277	NULL
0	NULL
7	NULL
171	NULL
+	NULL
3NC	NULL
(	NULL
802	NULL
)	NULL
Sequence	NULL
at	NULL
Exon/Intron	NULL
Junction	NULL
5	NULL
'	NULL
Donor	NULL
Exon	NULL
Intron	NULL
3	NULL
'	NULL
Acceptor	NULL
Exon	NULL
TGGTGGAG	NULL
gtgaggga	NULL
--	NULL
-ccttttag	NULL
GAGGAAGT	NULL
ATTTTCAG	NULL
gtattgat	NULL
--	NULL
-acttctag	NULL
CCCCATGT	NULL
GCAAGCAG	NULL
gtaatgat	NULL
--	NULL
-ttttgtag	NULL
CcTectert	NULL
CAATCTAG	NULL
gtaagace	NULL
--	NULL
-ttctctag	NULL
GAGCTGCT	NULL
GAATGCTG	NULL
gtaagaag	NULL
--	NULL
-gttcttag	NULL
GATCCATC	NULL
TAAGACCT	NULL
gtaagtac	NULL
--	NULL
-ctttaaag	NULL
ATTACTGA	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Structural	NULL
organization	NULL
of	NULL
the	NULL
human	NULL
MAT2B	NULL
gene	NULL
.	NULL

The	NULL
MAT2A	NULL
gene	NULL
consists	NULL
of	NULL
seven	NULL
exons	NULL
and	NULL
six	NULL
introns	NULL
.	NULL

Shaded	NULL
boxes	NULL
represent	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
of	NULL
the	NULL
MAT	NULL
II	NULL
B	NULL
subunit	NULL
protein	NULL
.	NULL

The	NULL
length	NULL
of	NULL
each	NULL
exon	NULL
in	NULL
nucleotide	NULL
pairs	NULL
is	NULL
denoted	NULL
by	NULL
the	NULL
numbers	NULL
in	NULL
the	NULL
boxes	NULL
.	NULL

Asterisks	NULL
mark	NULL
the	NULL
translation	NULL
initiation	NULL
and	NULL
termination	NULL
sites	NULL
.	NULL

The	NULL
inset	NULL
table	NULL
indicates	NULL
the	NULL
exact	NULL
location	NULL
of	NULL
exons	NULL
and	NULL
introns	NULL
and	NULL
the	NULL
sequence	NULL
at	NULL
each	NULL
exon/intron	NULL
junction	NULL
.	NULL

synthesized	NULL
and	NULL
end-labeled	NULL
with	NULL
[	NULL
y-	NULL
``	NULL
°PJIATP	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

Free	NULL
[	NULL
y-*°P	NULL
]	NULL
JATP	NULL
was	NULL
removed	NULL
by	NULL
the	NULL
QIAquick	NULL
nucleotide	NULL
removal	NULL
kit	NULL
(	NULL
Qiagen	NULL
)	NULL
.	NULL

Reverse	NULL
primer	NULL
extension	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
3	NULL
ug	NULL
of	NULL
mRNA	NULL
and	NULL
5	NULL
X	NULL
10°	NULL
cpm	NULL
of	NULL
the	NULL
labeled	NULL
primer	NULL
.	NULL

The	NULL
M18mp18	NULL
sequencing	NULL
ladder	NULL
was	NULL
prepared	NULL
by	NULL
fmol	NULL
sequencing	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
run	NULL
alongside	NULL
the	NULL
samples	NULL
on	NULL
8	NULL
%	NULL
urea/polyacrylamide	NULL
gels	NULL
as	NULL
a	NULL
size	NULL
marker	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
Promoter-We	NULL
cloned	NULL
and	NULL
sequenced	NULL
3.5	NULL
kbp	NULL
of	NULL
the	NULL
-flanking	NULL
DNA	NULL
of	NULL
the	NULL
human	NULL
MAT2B	NULL
gene	NULL
.	NULL

The	NULL
promoter	NULL
was	NULL
contained	NULL
within	NULL
1.1	NULL
kbp	NULL
.	NULL

The	NULL
primers	NULL
5-WP	NULL
(	NULL
5'-GCTC-GAGTAAGATGATCTTGGC	NULL
)	NULL
and	NULL
3'-WP	NULL
(	NULL
5-GAAGCTTGCCCGC-CGTCTTCAC	NULL
)	NULL
were	NULL
designed	NULL
to	NULL
amplify	NULL
the	NULL
region	NULL
-998/+204	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

The	NULL
primers	NULL
introduced	NULL
an	NULL
XhoI	NULL
site	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
and	NULL
a	NULL
HindIII	NULL
site	NULL
at	NULL
the	NULL
3	NULL
``	NULL
end	NULL
of	NULL
the	NULL
cloned	NULL
promoter	NULL
.	NULL

The	NULL
Pfu-amplified	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
pGEM-TEasy	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cloned	NULL
MAT2B	NULL
promoter	NULL
was	NULL
sequenced	NULL
in	NULL
both	NULL
directions	NULL
with	NULL
overlapping	NULL
segments	NULL
to	NULL
verify	NULL
the	NULL
sequence	NULL
and	NULL
confirm	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
cloned	NULL
promoter	NULL
.	NULL

The	NULL
cloned	NULL
promoter	NULL
DNA	NULL
was	NULL
excised	NULL
from	NULL
the	NULL
pGEM-TEasy	NULL
vector	NULL
by	NULL
digestion	NULL
with	NULL
and	NULL
HindIII	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
purified	NULL
,	NULL
and	NULL
processed	NULL
as	NULL
described	NULL
below	NULL
.	NULL

Generation	NULL
of	NULL
Luciferase	NULL
Reporter	NULL
Constructs	NULL
of	NULL
the	NULL
MAT2B	NULL
Promot-er-A	NULL
1.1-kbp	NULL
Xhol/HindIII-digested	NULL
fragment	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
containing	NULL
the	NULL
5'-flanking	NULL
region	NULL
starting	NULL
at	NULL
position	NULL
+204	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
was	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
firefly	NULL
luciferase	NULL
reporter	NULL
gene	NULL
in	NULL
the	NULL
pGL8-Enhancer	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Directional	NULL
insertion	NULL
was	NULL
verified	NULL
by	NULL
restriction	NULL
digestion	NULL
and	NULL
by	NULL
sequencing	NULL
the	NULL
clone	NULL
from	NULL
both	NULL
directions	NULL
.	NULL

Subsequent	NULL
deletion	NULL
constructs	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
using	NULL
sequence-specific	NULL
primers	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
containing	NULL
the	NULL
restriction	NULL
sites	NULL
XhoUHindIII	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
purified	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
pGEM-TEasy	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
sequenced	NULL
for	NULL
ver-ification	NULL
.	NULL

The	NULL
cloned	NULL
deletion	NULL
constructs	NULL
were	NULL
excised	NULL
from	NULL
the	NULL
pGEM-TEasy	NULL
vector	NULL
using	NULL
Xhol/HindIlII	NULL
and	NULL
then	NULL
cloned	NULL
upstream	NULL
from	NULL
the	NULL
firefly	NULL
luciferase	NULL
gene	NULL
into	NULL
the	NULL
pGL3-Enhancer	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

All	NULL
constructs	NULL
were	NULL
verified	NULL
by	NULL
sequence	NULL
analysis	NULL
.	NULL

In	NULL
Vivo	NULL
Analysis	NULL
of	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
Activity-The	NULL
functional	NULL
expression	NULL
of	NULL
the	NULL
pGL3-MAT2B	NULL
promoter	NULL
deletion	NULL
constructs	NULL
was	NULL
analyzed	NULL
in	NULL
Cos-1	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
as	NULL
detailed	NULL
elsewhere	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Analysis	NULL
of	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
Activity	NULL
by	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
Supershift	NULL
Assays-Double-stranded	NULL
oligo-	NULL
nucleotide	NULL
probes	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
amplification	NULL
with	NULL
``	NULL
°P	NULL
end	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
24920	NULL
M13mp18	NULL
Ladder	NULL
.—	NULL
'	NULL
te	NULL
Bra2	NULL
Bral	NULL
227bp	NULL
|	NULL
-m	NULL
wa	NULL
225bp	NULL
-m	NULL
..	NULL
a224	NULL
-222	NULL
‘	NULL
t	NULL
-220	NULL
...	NULL
-216	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Transcription	NULL
initiation	NULL
of	NULL
the	NULL
human	NULL
MAT2B	NULL
gene	NULL
as	NULL
determined	NULL
by	NULL
primer	NULL
extension	NULL
analysis	NULL
.	NULL

Two	NULL
primers	NULL
starting	NULL
at	NULL
MAT2B	NULL
cDNA	NULL
sequence	NULL
+22	NULL
(	NULL
Bral	NULL
)	NULL
and	NULL
+24	NULL
(	NULL
Bra2	NULL
)	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
translation	NULL
initiation	NULL
site	NULL
were	NULL
annealed	NULL
to	NULL
human	NULL
lymphocyte	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
and	NULL
extended	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
.	NULL

Extension	NULL
products	NULL
of	NULL
225	NULL
and	NULL
227	NULL
bases	NULL
in	NULL
length	NULL
were	NULL
observed	NULL
,	NULL
indicating	NULL
that	NULL
transcription	NULL
starts	NULL
203	NULL
bases	NULL
upstream	NULL
of	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

An	NULL
M18mp18	NULL
sequencing	NULL
reaction	NULL
was	NULL
used	NULL
as	NULL
a	NULL
size	NULL
marker	NULL
.	NULL

The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
labeled	NULL
primers	NULL
.	NULL

The	NULL
amplified	NULL
DNA	NULL
representing	NULL
specific	NULL
regions	NULL
of	NULL
the	NULL
proximal	NULL
promoter	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
was	NULL
generated	NULL
using	NULL
the	NULL
primers	NULL
listed	NULL
in	NULL
Table	NULL
I.	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
20-ul	NULL
final	NULL
volume	NULL
by	NULL
incubating	NULL
60	NULL
fmol	NULL
(	NULL
~50,000	NULL
epm	NULL
)	NULL
of	NULL
``	NULL
°P-labeled	NULL
probe	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
crude	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA	NULL
in	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
6	NULL
ug	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
for	NULL
40	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
conducted	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
specific	NULL
or	NULL
nonspecific	NULL
competitors	NULL
,	NULL
both	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
.	NULL

Specific	NULL
competitors	NULL
were	NULL
cold	NULL
probes	NULL
;	NULL
nonspecific	NULL
competitors	NULL
were	NULL
unlabeled	NULL
PCR	NULL
amplification	NULL
products	NULL
of	NULL
an	NULL
unrelated	NULL
DNA	NULL
sequence	NULL
,	NULL
free	NULL
of	NULL
sites	NULL
of	NULL
interest	NULL
,	NULL
and	NULL
similar	NULL
in	NULL
size	NULL
to	NULL
specific	NULL
competitor	NULL
.	NULL

An	NULL
Spl-specific	NULL
competitor	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC	NULL
2502	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
:	NULL
protein	NULL
complexes	NULL
formed	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
on	NULL
nondenaturing	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
pre-run	NULL
for	NULL
1	NULL
h	NULL
at	NULL
100	NULL
V	NULL
,	NULL
and	NULL
electrophoresis	NULL
was	NULL
conducted	NULL
at	NULL
a	NULL
30-mAmp	NULL
constant	NULL
current	NULL
.	NULL

Supershift	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
antibodies	NULL
(	NULL
Abs	NULL
)	NULL
to	NULL
specific	NULL
factors	NULL
that	NULL
have	NULL
corresponding	NULL
recognition	NULL
elements	NULL
within	NULL
the	NULL
MAT2B	NULL
promoter	NULL
region	NULL
analyzed	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
above	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
an	NULL
Ab	NULL
specific	NULL
to	NULL
one	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
of	NULL
interest	NULL
.	NULL

The	NULL
Ab	NULL
was	NULL
premixed	NULL
with	NULL
the	NULL
nuclear	NULL
extract	NULL
,	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
radiolabeled	NULL
probe	NULL
,	NULL
or	NULL
added	NULL
after	NULL
the	NULL
binding	NULL
reaction	NULL
-1071	NULL
GAAATGAGTTTTTGTTGGGCGGTTCAGGAGGAAGGAAAGTCATGGTGTTCTGACGTGGAAAACTTCT	NULL
-1005	NULL
TTAAAAGGCTGCTTAGTCTTTAGTTTGAAAATAAACCAAAAAGGTTTAGGAGTCGGGGAAAGGCCC	NULL
-939	NULL
TAGGAAAATCCAGACAGTGGTCACGTTTGTGGACGACGTTTAGAGCTTGCTATCCTGCGCACACAA	NULL
-873	NULL
GARACCCTTGGACTGTTCGGTGCAAAGTTGGCAAATCCTACACGGCCTGTGCCAGGGTTTACTTTCT	NULL
-807	NULL
GCATCAATTTCACAGGCGTCCAGCCTGGCTGAGGACTTTTTGCGGTTTTTAACTGGAAGGGAAATA	NULL
-741	NULL
AGTCGGCATCAGCACTTAGGGCTGCTTAACTTTTAAAAGGTGGTAGAACGCCCAGCCTTACACGCT	NULL
-675	NULL
GCTGCTTAAATTCTCGGTGCTCACCAAGCCTGGGCTCGTGTGGCCCAATCCTECAATCCCCGAGGC	NULL
AP-2	NULL
-609	NULL
GGTGTTTCTTAAAGAGTGGGCTTGATTCTGGTTAAACCCATTAAGAAGTCGGACCCCGGGCTCGTT	NULL
GR	NULL
NFIL6	NULL
NF-L	NULL
-543	NULL
TCTEGTTCTGTAATTATGGGTAAAGTCCAAGGATCTGCGTTTTGAACAGGTACCTAAGTAGTTCAT	NULL
GATA-1	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Sequence	NULL
of	NULL
the	NULL
5'-flanking	NULL
-477	NULL
CTTCCTTCCCCCTACAACTTTTTATTTTTAATTAGTTAAAAATAGTTTTACATTTTTGATATCTCA	NULL
region	NULL
of	NULL
the	NULL
human	NULL
MAT2B	NULL
gene	NULL
.	NULL

Depicted	NULL
is	NULL
1.1	NULL
kb	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
5	NULL
'	NULL
EA3	NULL
PJ	NULL
-411	NULL
CACACAGGTTTTTTCTTTTTTTAAGCATCCCAGGAACACAAATGGCTCAGACGCCAACCCTTTTAT	NULL
-	NULL
ave	NULL
TELD	NULL
NEA	NULL
flanking	NULL
sequence	NULL
.	NULL

The	NULL
transcription	NULL
-345	NULL
TTPTATTCCTTGTCTTTTTCTAAATCTETTCAAAACCCCCACCTAGAGCTCTAGAGATCTGTCCATT	NULL
start	NULL
site	NULL
is	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
.	NULL

Puta-	NULL
Sp1	NULL
NFA	NULL
tive	NULL
sites	NULL
for	NULL
known	NULL
transcription	NULL
factors	NULL
-279	NULL
ATGCTCTACCCACCTCCGCCCCCGCCCCCATGACTTTAAAATGCTTTTTATTCCACTTTTTATATT	NULL
are	NULL
underlined	NULL
.	NULL

Sp1	NULL
_	NULL
Sp1	NULL
-213	NULL
GCTCAGTCGATCCTCATGCACTGCGCAGTCTGCAAACTTGAAACTCAAGGCGATCCACTTCAATCT	NULL
PEA3	NULL
TBF	NULL
-147	NULL
TTTCCCGAGTCAAGAAAAAAAGGAAAAAAAGTAGAATAAAAAGCACTCAAATAAAATCTCCGAAAC	NULL
TBF	NULL
-81	NULL
AAAACCTGAATTCACTGCCTAAGGTCAGGGCCTTTCTTTTGTGTGTCGCTTTAACCATCGGCGCGT	NULL
TSS	NULL
Sp1	NULL
Sp1	NULL
NFA	NULL
NFI	NULL
-15	NULL
GGGCTGGGGCCAGACCGCGCGTACCCGCCCTCTTTCTGGGGCGTCGCCGGAGCCTGGCCAATCAAC	NULL
Sp1	NULL
+52	NULL
GGGCGCGGCTATGGCAGCGGAAGCCGCAAGCCGCGAGCGGGGTCGTTCTGGGCCTAGGGGAGGCGG	NULL
+118	NULL
GCCGAGGCCGTCTGAGCTGAGGCCCGCGTCCATCCTGGGTTGGCAGCAGGTGGCGECCGCTGAGGCT	NULL
SpL	NULL
+184	NULL
GCGGC	NULL
@	NULL
Tcaacaceecee	NULL
@	NULL
caTe	NULL
pGL3-MAT2B	NULL
(	NULL
-998	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
-826	NULL
)	NULL
[	NULL
Luc	NULL
}	NULL
pGL3-MAT2B	NULL
(	NULL
-596	NULL
)	NULL
@	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
-483	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
-363	NULL
)	NULL
[	NULL
Luc	NULL
}	NULL
pGL3-MAT2B	NULL
(	NULL
-237	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
-174	NULL
)	NULL
[	NULL
Iuc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
115	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
4	NULL
)	NULL
m	NULL
pGL3-MAT2B	NULL
(	NULL
+52	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
+93	NULL
)	NULL
[	NULL
Luc	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
+154	NULL
)	NULL
[	NULL
Lue	NULL
>	NULL
pGL3	NULL
{	NULL
Luc	NULL
,	NULL
)	NULL
|	NULL
T	NULL
T	NULL
0	NULL
25	NULL
50	NULL
75	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

In	NULL
vivo	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
MAT2B	NULL
gene	NULL
promoter	NULL
constructs	NULL
.	NULL

A	NULL
series	NULL
of	NULL
MAT2B	NULL
promoter	NULL
deletion	NULL
constructs	NULL
fused	NULL
to	NULL
the	NULL
firefly	NULL
luciferase	NULL
reporter	NULL
were	NULL
transfected	NULL
into	NULL
Cos-1	NULL
cells	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
the	NULL
dual	NULL
luciferase	NULL
reporter	NULL
assay	NULL
system	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
data	NULL
were	NULL
calculated	NULL
in	NULL
relative	NULL
luciferase	NULL
units	NULL
and	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
pGL8-MAT2B	NULL
(	NULL
-998	NULL
)	NULL
con-struct	NULL
,	NULL
which	NULL
was	NULL
set	NULL
at	NULL
100	NULL
%	NULL
activity	NULL
.	NULL

Data	NULL
presented	NULL
are	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
at	NULL
least	NULL
four	NULL
separate	NULL
experiments	NULL
,	NULL
each	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

An	NULL
almost	NULL
identical	NULL
pattern	NULL
was	NULL
seen	NULL
when	NULL
the	NULL
pGL3-MAT2B	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
the	NULL
Jurkat	NULL
human	NULL
leukemia	NULL
cell	NULL
line	NULL
by	NULL
the	NULL
100	NULL
method	NULL
described	NULL
previously	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Percentage	NULL
of	NULL
Whole	NULL
MAT2B	NULL
Promoter	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
~115	NULL
+204	NULL
115	NULL
--	NULL
<	NULL
+52	NULL
~115	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-4	NULL
-__-	NULL
452	NULL
«	NULL
4	NULL
-__-	NULL
+204	NULL
+52	NULL
--	NULL
-	NULL
+93	NULL
1_	NULL
2	NULL
3	NULL
1_	NULL
2	NULL
3	NULL
1	NULL
2	NULL
3	NULL
1	NULL
2	NULL
3	NULL
A	NULL
B	NULL
C	NULL
D	NULL
-115/+52	NULL
-115/-4	NULL
~4/+52	NULL
+52/493	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

In	NULL
vitro	NULL
analysis	NULL
of	NULL
the	NULL
MAT2B	NULL
proximal	NULL
promoter	NULL
by	NULL
EMSA	NULL
.	NULL

Probes	NULL
used	NULL
for	NULL
EMSA	NULL
and	NULL
supershift	NULL
analyses	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
cell	NULL
extracts	NULL
are	NULL
indicated	NULL
,	NULL
and	NULL
only	NULL
those	NULL
that	NULL
show	NULL
relevant	NULL
patterns	NULL
are	NULL
shown	NULL
.	NULL

For	NULL
each	NULL
autoradiogram	NULL
,	NULL
Zane	NULL
I	NULL
is	NULL
probe	NULL
alone	NULL
,	NULL
lane	NULL
2	NULL
is	NULL
probe	NULL
plus	NULL
Jurkat	NULL
nuclear	NULL
cell	NULL
extract	NULL
,	NULL
and	NULL
lane	NULL
3	NULL
is	NULL
probe	NULL
and	NULL
Jurkat	NULL
nuclear	NULL
cell	NULL
extract	NULL
plus	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
relevant	NULL
nonradioactive	NULL
probe	NULL
.	NULL

was	NULL
completed	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
following	NULL
Abs	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
were	NULL
used	NULL
in	NULL
supershift	NULL
analyses	NULL
:	NULL
rabbit	NULL
polyclonal	NULL
anti-Spl	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC-59X	NULL
)	NULL
,	NULL
anti-Sp2	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC-648X	NULL
)	NULL
,	NULL
anti-5p3	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC-644X	NULL
)	NULL
,	NULL
anti-5p4	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC-645X	NULL
)	NULL
,	NULL
and	NULL
anti-NF1L	NULL
monoclonal	NULL
Ab	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

SC-870X	NULL
)	NULL
.	NULL

Chromatin	NULL
Immunoprecipitation-Cross-linking	NULL
between	NULL
transcription	NULL
factors	NULL
and	NULL
chromatin	NULL
was	NULL
achieved	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
following	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Yang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
82	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
formaldehyde	NULL
was	NULL
added	NULL
to	NULL
cells	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
%	NULL
for	NULL
10	NULL
min	NULL
,	NULL
and	NULL
0.125	NULL
M	NULL
glycine	NULL
was	NULL
used	NULL
to	NULL
stop	NULL
the	NULL
reaction	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
cold	NULL
PBS	NULL
and	NULL
once	NULL
with	NULL
PBS	NULL
containing	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
and	NULL
then	NULL
lysed	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
cell	NULL
lysis	NULL
buffer	NULL
(	NULL
5	NULL
mM	NULL
Pipes-KOH	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
85	NULL
mM	NULL
KCl	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Nonidet	NULL
P-40	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
100	NULL
ng/ml	NULL
leupeptin	NULL
,	NULL
100	NULL
ng/m	NULL
!	NULL

aprotinin	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
homogenized	NULL
,	NULL
and	NULL
the	NULL
nuclei	NULL
were	NULL
recovered	NULL
by	NULL
centrifugation	NULL
at	NULL
250	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
and	NULL
resus-pended	NULL
in	NULL
0.2	NULL
ml	NULL
of	NULL
nuclear	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
10	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
SDS	NULL
plus	NULL
the	NULL
protease	NULL
inhibitors	NULL
.	NULL

The	NULL
lysate	NULL
was	NULL
sonicated	NULL
to	NULL
shear	NULL
the	NULL
chromatin	NULL
to	NULL
an	NULL
average	NULL
length	NULL
of	NULL
<	NULL
2	NULL
kb	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
diluted	NULL
10-fold	NULL
with	NULL
the	NULL
immunoprecipitation	NULL
dilution	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Triton	NULL
X-100	NULL
,	NULL
16.7	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
1.2	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
167	NULL
mM	NULL
NaCl	NULL
plus	NULL
the	NULL
protease	NULL
inhibitors	NULL
)	NULL
.	NULL

A	NULL
240-ul	NULL
slurry	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA/protein	NULL
A-agarose	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
was	NULL
added	NULL
to	NULL
reduce	NULL
nonspecific	NULL
binding	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
rotated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
then	NULL
centrifuged	NULL
at	NULL
500	NULL
%	NULL
g	NULL
for	NULL
1	NULL
min	NULL
.	NULL

Precleared	NULL
chromatin	NULL
solutions	NULL
were	NULL
incubated	NULL
with	NULL
antibody	NULL
to	NULL
Spl	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
,	NULL
Sp3	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
or	NULL
no	NULL
antibody	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
and	NULL
rotated	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
12	NULL
h.	NULL
Immune	NULL
complexes	NULL
were	NULL
collected	NULL
by	NULL
adding	NULL
80	NULL
pul	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA/protein	NULL
A-agarose	NULL
slurry	NULL
for	NULL
4	NULL
h	NULL
with	NULL
rotation	NULL
.	NULL

Samples	NULL
were	NULL
washed	NULL
four	NULL
times	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
wash	NULL
buffer	NULL
(	NULL
0.1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
Triton	NULL
X-100	NULL
,	NULL
20	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
EDTA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
immunoprecipitated	NULL
material	NULL
was	NULL
eluted	NULL
by	NULL
three	NULL
successive	NULL
5-min	NULL
incubations	NULL
with	NULL
150	NULL
ul	NULL
of	NULL
elution	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
SDS	NULL
and	NULL
50	NULL
mM	NULL
NaHCO	NULL
,	NULL
)	NULL
.	NULL

To	NULL
reverse	NULL
the	NULL
formalde-hyde-induced	NULL
cross-linking	NULL
,	NULL
the	NULL
eluates	NULL
were	NULL
pooled	NULL
,	NULL
NaCl	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.3	NULL
M	NULL
,	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
incubated	NULL
at	NULL
65	NULL
°C	NULL
for	NULL
4	NULL
h.	NULL
This	NULL
step	NULL
was	NULL
followed	NULL
by	NULL
digestion	NULL
in	NULL
10	NULL
ul	NULL
of	NULL
2	NULL
M	NULL
Tris	NULL
,	NULL
pH	NULL
6.8	NULL
,	NULL
10	NULL
pul	NULL
of	NULL
0.5	NULL
M	NULL
EDTA	NULL
,	NULL
and	NULL
2	NULL
ul	NULL
of	NULL
proteinase	NULL
K	NULL
(	NULL
20	NULL
mg/ml	NULL
)	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
45	NULL
°C	NULL
,	NULL
and	NULL
then	NULL
the	NULL
DNA	NULL
was	NULL
extracted	NULL
with	NULL
24921	NULL
phenol/CHC	NULL
]	NULL
,	NULL
followed	NULL
by	NULL
ethanol	NULL
precipitation	NULL
and	NULL
resuspension	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
sterile	NULL
H	NULL
,	NULL
O	NULL
.	NULL

Five	NULL
pl	NULL
of	NULL
DNA	NULL
solution	NULL
were	NULL
used	NULL
as	NULL
a	NULL
template	NULL
in	NULL
PCR	NULL
analysis	NULL
.	NULL

Primers	NULL
were	NULL
designed	NULL
to	NULL
amplify	NULL
the	NULL
regions	NULL
from	NULL
-174	NULL
or	NULL
-4	NULL
to	NULL
+	NULL
52	NULL
.	NULL

The	NULL
primer	NULL
5'-BP8	NULL
(	NULL
5-ACTCGAGAAACTCAAGGC-GATCCACTT	NULL
)	NULL
or	NULL
5'-BP9	NULL
(	NULL
5-CCTCGAGACCGCGCGTACC	NULL
)	NULL
was	NULL
paired	NULL
with	NULL
primer	NULL
3'-BP8	NULL
(	NULL
5'-TCTGCCCCCAGCCCACG	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
products	NULL
were	NULL
separated	NULL
on	NULL
1.5	NULL
%	NULL
agarose	NULL
gel	NULL
and	NULL
visualized	NULL
by	NULL
ethidium	NULL
bromide	NULL
staining	NULL
.	NULL

In	NULL
Vivo	NULL
and	NULL
in	NULL
Vitro	NULL
Analysis	NULL
of	NULL
the	NULL
Effect	NULL
of	NULL
MAT2B	NULL
Promoter	NULL
Mut-ations-Several	NULL
mutations	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
clones	NULL
pGL3-MA-T2B	NULL
(	NULL
-174	NULL
)	NULL
-LUC	NULL
,	NULL
pGL3-MAT2B	NULL
(	NULL
-115	NULL
)	NULL
-LUC	NULL
,	NULL
and	NULL
pGL3-MAT2B	NULL
(	NULL
-4	NULL
)	NULL
-LUC	NULL
according	NULL
to	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Wang	NULL
and	NULL
Wilkinson	NULL
(	NULL
33	NULL
)	NULL
that	NULL
targets	NULL
putative	NULL
factor	NULL
recognition	NULL
sites	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
TBF	NULL
site	NULL
at	NULL
-111/-105	NULL
was	NULL
generated	NULL
using	NULL
the	NULL
primers	NULL
5'-MU1	NULL
(	NULL
5'-GCT-CGAGAATAACAAGCACTCAAATAAAATCTCC	NULL
)	NULL
and	NULL
3'-MU1	NULL
(	NULL
5'-GAG-ATTTTATTTGAGTGCTTGTTATTCTCGAGCC	NULL
)	NULL
.	NULL

Another	NULL
possible	NULL
TBF	NULL
site	NULL
at	NULL
-95/-91	NULL
was	NULL
mutated	NULL
using	NULL
the	NULL
primers	NULL
5'-MU2	NULL
(	NULL
5'-GCACTC-AAATACCATCTCCGAAACAAAACCTG	NULL
)	NULL
and	NULL
3'-MU2	NULL
(	NULL
5'-CAGGTTTT-GTTTCGGAGATGGTATTTGAGTGC	NULL
)	NULL
.	NULL

The	NULL
TATA	NULL
box	NULL
at	NULL
-382/-28	NULL
was	NULL
mutated	NULL
with	NULL
oligos	NULL
5'-MU3	NULL
(	NULL
5'-CTTTTGTGTGTCGCTTTTTGCATCG-GCGCGTG	NULL
)	NULL
and	NULL
3'-MUS3	NULL
(	NULL
5'-CACGCGCCGATGCAAAAAGCGACACA-CAAAAG	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
position	NULL
+9/+15	NULL
was	NULL
generated	NULL
with	NULL
the	NULL
primers	NULL
5'-MU2	NULL
(	NULL
5'-CAGACCGCGCGTACCTTACCTCTTTC-TGG	NULL
)	NULL
and	NULL
3'-MU2	NULL
(	NULL
5'-CCAGAAAGAGGTAAGGTACGCGCGGTCTG	NULL
)	NULL
.	NULL

The	NULL
second	NULL
Spl	NULL
site	NULL
at	NULL
+23/+28	NULL
was	NULL
mutated	NULL
using	NULL
the	NULL
primers	NULL
5'-MUS	NULL
(	NULL
5'-CCTCTTTCTGGGTTTTCGGCGGAGCGTGGC	NULL
)	NULL
and	NULL
3'-MUS5	NULL
(	NULL
5'-GCCACGCTCCGCCGAAAACCCAGAAAGAGG	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
was	NULL
performed	NULL
on	NULL
promoter	NULL
constructs	NULL
by	NULL
PCR	NULL
using	NULL
Pfu	NULL
turbo	NULL
DNA	NULL
polymerase	NULL
(	NULL
Stratagene	NULL
)	NULL
and	NULL
the	NULL
oligos	NULL
listed	NULL
above	NULL
following	NULL
the	NULL
method	NULL
of	NULL
Wang	NULL
and	NULL
Wilkinson	NULL
(	NULL
83	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
after	NULL
the	NULL
PCR	NULL
reaction	NULL
the	NULL
product	NULL
was	NULL
incubated	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
Dpnl	NULL
(	NULL
Promega	NULL
)	NULL
to	NULL
remove	NULL
the	NULL
methylated	NULL
template	NULL
DNA	NULL
.	NULL

A	NULL
portion	NULL
of	NULL
the	NULL
digested	NULL
reaction	NULL
mix	NULL
was	NULL
analyzed	NULL
on	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
to	NULL
verify	NULL
the	NULL
PCR	NULL
product	NULL
size	NULL
.	NULL

E.	NULL
coli	NULL
strain	NULL
JM109	NULL
was	NULL
transformed	NULL
using	NULL
5	NULL
ul	NULL
of	NULL
the	NULL
PCR-amplified	NULL
vector	NULL
,	NULL
and	NULL
six	NULL
clones	NULL
of	NULL
each	NULL
transformation	NULL
were	NULL
sequenced	NULL
to	NULL
confirm	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
desired	NULL
muta-tions	NULL
.	NULL

The	NULL
mutated	NULL
DNA	NULL
products	NULL
were	NULL
excised	NULL
from	NULL
the	NULL
pGL8	NULL
vector	NULL
using	NULL
XAhol	NULL
and	NULL
HindIII	NULL
and	NULL
individually	NULL
recloned	NULL
into	NULL
an	NULL
unamplified	NULL
pGLS8-Enhancer	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
vector	NULL
itself	NULL
was	NULL
not	NULL
modified	NULL
during	NULL
the	NULL
mutagenesis	NULL
reaction	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
activity	NULL
of	NULL
each	NULL
mutant	NULL
construct	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
above	NULL
.	NULL

EMSA	NULL
probes	NULL
-115/-4	NULL
and	NULL
-4/+52	NULL
were	NULL
generated	NULL
by	NULL
using	NULL
the	NULL
mutated	NULL
pGL8-MAT2B	NULL
(	NULL
115	NULL
)	NULL
-LUC	NULL
clones	NULL
as	NULL
templates	NULL
and	NULL
external	NULL
primers	NULL
3'-BP8	NULL
(	NULL
5'-TCTGCCCCCAGCCCACG	NULL
)	NULL
and	NULL
3'-BP9	NULL
(	NULL
5'-GTTGATTG-GCCACGCTCC	NULL
)	NULL
.	NULL

Results	NULL
from	NULL
only	NULL
those	NULL
mutations	NULL
that	NULL
affected	NULL
promoter	NULL
activity	NULL
are	NULL
described	NULL
below	NULL
.	NULL

RESULTS	NULL
Genomic	NULL
Organization	NULL
of	NULL
the	NULL
MAT2B	NULL
Gene-Human	NULL
genomic	NULL
clone	NULL
22646	NULL
was	NULL
determined	NULL
to	NULL
harbor	NULL
the	NULL
MAT2B	NULL
gene	NULL
and	NULL
a	NULL
significant	NULL
portion	NULL
of	NULL
its	NULL
5'-flanking	NULL
sequence	NULL
.	NULL

A	NULL
series	NULL
of	NULL
primers	NULL
were	NULL
designed	NULL
,	NULL
based	NULL
on	NULL
the	NULL
known	NULL
MAT2B	NULL
cDNA	NULL
sequence	NULL
,	NULL
to	NULL
determine	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
.	NULL

The	NULL
gene	NULL
consisted	NULL
of	NULL
seven	NULL
exons	NULL
interrupted	NULL
by	NULL
six	NULL
introns	NULL
spanning	NULL
~6.8	NULL
kbp	NULL
of	NULL
genomic	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
sizes	NULL
and	NULL
locations	NULL
of	NULL
the	NULL
various	NULL
exons	NULL
and	NULL
introns	NULL
as	NULL
well	NULL
as	NULL
the	NULL
donor	NULL
and	NULL
acceptor	NULL
sequence	NULL
are	NULL
summarized	NULL
in	NULL
the	NULL
#	NULL
set	NULL
table	NULL
.	NULL

All	NULL
boundaries	NULL
were	NULL
found	NULL
to	NULL
conform	NULL
to	NULL
the	NULL
GT-AG	NULL
rule	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Exon	NULL
1	NULL
contained	NULL
203	NULL
bp	NULL
of	NULL
5'-noncoding	NULL
region	NULL
and	NULL
63	NULL
bp	NULL
of	NULL
coding	NULL
sequence	NULL
.	NULL

Exon	NULL
7	NULL
contained	NULL
171	NULL
bp	NULL
of	NULL
coding	NULL
sequence	NULL
and	NULL
802	NULL
bp	NULL
of	NULL
-untranslated	NULL
sequence	NULL
.	NULL

Chromosomal	NULL
Localization	NULL
of	NULL
the	NULL
Human	NULL
MAT2B	NULL
Subunit	NULL
Gene-A	NULL
total	NULL
of	NULL
80	NULL
metaphase	NULL
cells	NULL
was	NULL
analyzed	NULL
as	NULL
detailed	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
;	NULL
69	NULL
of	NULL
those	NULL
exhibited	NULL
specific	NULL
labeling	NULL
with	NULL
DNA	NULL
from	NULL
clone	NULL
22646	NULL
on	NULL
chromosome	NULL
5	NULL
.	NULL

An	NULL
anonymous	NULL
genomic	NULL
probe	NULL
,	NULL
previously	NULL
mapped	NULL
to	NULL
5q22	NULL
and	NULL
confirmed	NULL
by	NULL
cohybridization	NULL
with	NULL
a	NULL
probe	NULL
from	NULL
the	NULL
cri	NULL
du	NULL
chat	NULL
locus	NULL
,	NULL
hybridized	NULL
to	NULL
the	NULL
same	NULL
chromosome	NULL
as	NULL
clone	NULL
22646	NULL
,	NULL
confirming	NULL
the	NULL
location	NULL
as	NULL
the	NULL
long	NULL
arm	NULL
of	NULL
chromosome	NULL
5	NULL
.	NULL

Ten	NULL
individual	NULL
measurements	NULL
of	NULL
specifically	NULL
labeled	NULL
chromosome	NULL
5	NULL
demonstrated	NULL
that	NULL
the	NULL
22646	NULL
clone	NULL
hybridized	NULL
to	NULL
a	NULL
position	NULL
89	NULL
%	NULL
of	NULL
the	NULL
distance	NULL
from	NULL
the	NULL
centromere	NULL
to	NULL
the	NULL
telomere	NULL
of	NULL
5q	NULL
,	NULL
an	NULL
area	NULL
that	NULL
corresponded	NULL
to	NULL
the	NULL
interface	NULL
between	NULL
bands	NULL
5q34	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
24922	NULL
The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
A	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
_	NULL
7	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
``	NULL
3	NULL
wo	NULL
wa	NULL
.	NULL

-H	NULL
200bp	NULL
PCR	NULL
Analysis	NULL
of	NULL
CHIP	NULL
Probe	NULL
(	NULL
+52/+93	NULL
)	NULL
Probe	NULL
(	NULL
-Al+52	NULL
)	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Involvement	NULL
of	NULL
different	NULL
members	NULL
of	NULL
the	NULL
Spl	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
protein-DNA	NULL
complexes	NULL
formed	NULL
on	NULL
the	NULL
MAT2B	NULL
promoter	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
supershift	NULL
with	NULL
antibodies	NULL
to	NULL
NF1	NULL
and	NULL
different	NULL
members	NULL
of	NULL
the	NULL
Sp1	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Lane	NULL
1	NULL
is	NULL
probe	NULL
alone	NULL
,	NULL
lane	NULL
2	NULL
is	NULL
probe	NULL
plus	NULL
Jurkat	NULL
nuclear	NULL
cell	NULL
extract	NULL
,	NULL
and	NULL
lanes	NULL
3-6	NULL
are	NULL
supershift	NULL
with	NULL
anti-Sp1	NULL
,	NULL
-8p2	NULL
,	NULL
-8p3	NULL
,	NULL
and	NULL
-Sp4	NULL
Abs	NULL
,	NULL
respectively	NULL
.	NULL

Lane	NULL
7	NULL
is	NULL
supershift	NULL
with	NULL
an	NULL
anti-NF1	NULL
antibody	NULL
.	NULL

Complexes	NULL
are	NULL
designated	NULL
I	NULL
and	NULL
II	NULL
in	NULL
order	NULL
of	NULL
mobility	NULL
.	NULL

C	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
interaction	NULL
of	NULL
Spl	NULL
and	NULL
Sp8	NULL
with	NULL
the	NULL
MAT2B	NULL
promoter	NULL
using	NULL
chromatin	NULL
immunoprecipitation	NULL
.	NULL

Shown	NULL
is	NULL
an	NULL
ethidium	NULL
bromide-stained	NULL
1.5	NULL
%	NULL
agarose	NULL
gel	NULL
showing	NULL
PCR	NULL
analysis	NULL
of	NULL
complexes	NULL
immunoprecipitated	NULL
with	NULL
Spl	NULL
or	NULL
Sp3	NULL
antibodies	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
with	NULL
the	NULL
immunoprecipitates	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Lane	NULL
a	NULL
is	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
PCR	NULL
reaction	NULL
and	NULL
represents	NULL
amplification	NULL
with	NULL
primers	NULL
for	NULL
the	NULL
region	NULL
from	NULL
-174	NULL
to	NULL
-4	NULL
using	NULL
the	NULL
pGLS-MAT2B	NULL
plasmid	NULL
as	NULL
template	NULL
;	NULL
lane	NULL
b	NULL
is	NULL
a	NULL
negative	NULL
control	NULL
consisting	NULL
of	NULL
samples	NULL
processed	NULL
through	NULL
the	NULL
chromatin	NULL
immunoprecipitation	NULL
protocol	NULL
(	NULL
CHIP	NULL
)	NULL
without	NULL
the	NULL
primary	NULL
antibody	NULL
;	NULL
lanes	NULL
c	NULL
and	NULL
d	NULL
are	NULL
samples	NULL
processed	NULL
through	NULL
the	NULL
chromatin	NULL
immunoprecipitation	NULL
protocol	NULL
with	NULL
either	NULL
an	NULL
Spl	NULL
or	NULL
Sp3	NULL
antibody	NULL
.	NULL

Primers	NULL
were	NULL
designed	NULL
to	NULL
amplify	NULL
the	NULL
regions	NULL
from	NULL
-174	NULL
or	NULL
-4	NULL
to	NULL
+	NULL
52	NULL
.	NULL

-115	NULL
AGAATAAAAAGCACTCAAATAAAATCTCCGAAACAAAACCTGAATTCACTGCCTAAGG	NULL
TATA	NULL
TSS	NULL
TCAGGGCCTTTCTTTTGTGTGTCGCTTTAAGCATCGGCGCGTGGGCTGGGGGCAGACCGCG	NULL
Sp1	NULL
Sp1	NULL
CGTACCCGCCCTCTTTCrGeGeeceTCceecCGGAaGCGTGGCCAATCAACG	NULL
+52	NULL
SITE	NULL
FORM	NULL
LOCATION/SEQUENCE	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
TATA	NULL
WT	NULL
-32	NULL
TTTAA	NULL
-28	NULL
Mu	NULL
-32	NULL
TTTIT	NULL
-28	NULL
Spl	NULL
WT	NULL
+9	NULL
CCCGCCC	NULL
+15	NULL
Mu	NULL
+9	NULL
CCTTACC	NULL
+15	NULL
Sp1	NULL
wT	NULL
+23	NULL
GGGGCG	NULL
+28	NULL
Mu	NULL
+23	NULL
GGGTIT	NULL
+28	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
mutating	NULL
specific	NULL
factor	NULL
recognition	NULL
sites	NULL
on	NULL
MAT2B	NULL
,	NULL
,	NULL
i	NULL
promoter	NULL
on	NULL
EMSA	NULL
.	NULL

The	NULL
position	NULL
of	NULL
wT	NULL
Spl	NULL
-	NULL
TATA	NULL
wT	NULL
Spl	NULL
SpI	NULL
each	NULL
mutation	NULL
is	NULL
indicated	NULL
by	NULL
underiines	NULL
,	NULL
___	NULL
319/+15	NULL
:32/-28	NULL
_	NULL
19/15	NULL
4230428	NULL
and	NULL
the	NULL
resultant	NULL
sequence	NULL
is	NULL
shown	NULL
in	NULL
P_NE	NULL
__P	NULL
NE	NULL
P	NULL
NE	NULL
B	NULL
P_NE	NULL
_P	NULL
NE	NULL
P	NULL
NE	NULL
the	NULL
inset	NULL
table	NULL
.	NULL

Indicated	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
A	NULL
or	NULL
mutated	NULL
(	NULL
Mx	NULL
)	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extract	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
analysis	NULL
as	NULL
detailed	NULL
in	NULL
the	NULL
g	NULL
u	NULL
Fig	NULL
.	NULL

5	NULL
legend	NULL
.	NULL

The	NULL
data	NULL
show	NULL
the	NULL
dramatic	NULL
.	NULL

i	NULL
effect	NULL
of	NULL
mutating	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9/+15	NULL
.	NULL

C	NULL
P	NULL
,	NULL
probe	NULL
alone	NULL
;	NULL
NE	NULL
,	NULL
nuclear	NULL
extract	NULL
.	NULL

me	NULL
Ww	NULL
d	NULL
P	NULL
~115/+52	NULL
~4/4+52	NULL
and	NULL
5q35.1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

analysis	NULL
.	NULL

Two	NULL
primers	NULL
,	NULL
Bral	NULL
and	NULL
Bra2	NULL
,	NULL
corresponding	NULL
to	NULL
+22	NULL
Mapping	NULL
the	NULL
MAT2B	NULL
Gene	NULL
Transcription	NULL
Start	NULL
Site-The	NULL
-	NULL
and	NULL
+24	NULL
of	NULL
the	NULL
MAT2B	NULL
open	NULL
reading	NULL
frame	NULL
were	NULL
annealed	NULL
to	NULL
transcription	NULL
start	NULL
site	NULL
was	NULL
identified	NULL
by	NULL
primer	NULL
extension	NULL
-	NULL
mRNA	NULL
prepared	NULL
from	NULL
normal	NULL
human	NULL
lymphocytes	NULL
and	NULL
ex	NULL
The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
tended	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
primer	NULL
Bra2	NULL
yielded	NULL
a	NULL
227-bp	NULL
product	NULL
,	NULL
and	NULL
Bral	NULL
yielded	NULL
a	NULL
225-bp	NULL
product	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
transcription	NULL
was	NULL
shown	NULL
to	NULL
start	NULL
203	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
MAT2B	NULL
translation	NULL
start	NULL
site	NULL
.	NULL

Cloning	NULL
and	NULL
Sequencing	NULL
of	NULL
the	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
Promot-er-The	NULL
sequence	NULL
of	NULL
~1.1	NULL
kbp	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

The	NULL
sequence	NULL
from	NULL
-15	NULL
to	NULL
+	NULL
203	NULL
in	NULL
the	NULL
5'-flanking	NULL
region	NULL
is	NULL
high	NULL
in	NULL
GC	NULL
content	NULL
with	NULL
clusters	NULL
of	NULL
overlapping	NULL
Spl	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

A	NULL
TATA	NULL
box	NULL
is	NULL
located	NULL
32	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

In	NULL
Vivo	NULL
Analysis	NULL
of	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
Activity-A	NULL
series	NULL
of	NULL
promoter	NULL
deletion	NULL
constructs	NULL
coupled	NULL
to	NULL
a	NULL
firefly	NULL
luciferase	NULL
reporter	NULL
gene	NULL
in	NULL
a	NULL
pGL3-Enhancer	NULL
vector	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
and	NULL
used	NULL
to	NULL
analyze	NULL
functional	NULL
expression	NULL
in	NULL
Cos-1	NULL
and	NULL
Jurkat	NULL
human	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

There	NULL
was	NULL
little	NULL
difference	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
pGL3-MAT2B	NULL
promoter	NULL
constructs	NULL
in	NULL
both	NULL
types	NULL
of	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Successive	NULL
deletions	NULL
from	NULL
-998	NULL
to	NULL
-115	NULL
of	NULL
the	NULL
MAT2B	NULL
promoter	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
promoter	NULL
activity	NULL
;	NULL
however	NULL
,	NULL
further	NULL
deletions	NULL
resulted	NULL
in	NULL
a	NULL
gradual	NULL
decrease	NULL
of	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Little	NULL
to	NULL
no	NULL
promoter	NULL
activity	NULL
was	NULL
seen	NULL
when	NULL
only	NULL
the	NULL
region	NULL
from	NULL
+93	NULL
to	NULL
+204	NULL
was	NULL
included	NULL
in	NULL
the	NULL
construct	NULL
.	NULL

The	NULL
region	NULL
from	NULL
+52	NULL
to	NULL
+93	NULL
provided	NULL
minimal	NULL
promoter	NULL
activity	NULL
,	NULL
and	NULL
the	NULL
inclusion	NULL
of	NULL
sequences	NULL
between	NULL
-4	NULL
and	NULL
+52	NULL
significantly	NULL
increased	NULL
activity	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
the	NULL
5'-noncoding	NULL
sequences	NULL
of	NULL
MAT2B	NULL
are	NULL
contributing	NULL
to	NULL
promoter	NULL
function	NULL
.	NULL

Another	NULL
significant	NULL
enhancement	NULL
in	NULL
promoter	NULL
activity	NULL
was	NULL
seen	NULL
when	NULL
sequences	NULL
between	NULL
positions	NULL
-115	NULL
and	NULL
-4	NULL
were	NULL
also	NULL
included	NULL
.	NULL

Functional	NULL
studies	NULL
described	NULL
below	NULL
indicated	NULL
that	NULL
this	NULL
enhancement	NULL
was	NULL
conferred	NULL
by	NULL
the	NULL
inclusion	NULL
of	NULL
a	NULL
TATA	NULL
sequence	NULL
at	NULL
position	NULL
-32/-8	NULL
.	NULL

No	NULL
further	NULL
enhancement	NULL
was	NULL
observed	NULL
when	NULL
additional	NULL
upstream	NULL
sequences	NULL
were	NULL
included	NULL
.	NULL

Together	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
sequences	NULL
between	NULL
+52	NULL
and	NULL
+93	NULL
provide	NULL
minimal	NULL
promoter	NULL
activity	NULL
,	NULL
whereas	NULL
sequences	NULL
between	NULL
-115	NULL
and	NULL
+93	NULL
provide	NULL
the	NULL
full	NULL
promoter	NULL
activity	NULL
.	NULL

Identification	NULL
of	NULL
Functional	NULL
Sites	NULL
in	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
Activity	NULL
by	NULL
EMSA	NULL
and	NULL
Supershift	NULL
Assays-Analysis	NULL
of	NULL
the	NULL
proximal	NULL
MAT2B	NULL
promoter	NULL
sequence	NULL
identified	NULL
several	NULL
putative	NULL
recognition	NULL
sites	NULL
for	NULL
known	NULL
transcription	NULL
factors	NULL
.	NULL

These	NULL
regions	NULL
were	NULL
subjected	NULL
to	NULL
further	NULL
functional	NULL
analysis	NULL
using	NULL
EMSA	NULL
,	NULL
supershift	NULL
assays	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
specific	NULL
sites	NULL
.	NULL

Competition	NULL
experiments	NULL
showed	NULL
that	NULL
the	NULL
complexes	NULL
that	NULL
formed	NULL
on	NULL
a	NULL
probe	NULL
representing	NULL
the	NULL
region	NULL
from	NULL
-115	NULL
to	NULL
-4	NULL
were	NULL
nonspecific	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
strong	NULL
and	NULL
specific	NULL
complexes	NULL
were	NULL
formed	NULL
on	NULL
a	NULL
probe	NULL
representing	NULL
the	NULL
region	NULL
from	NULL
-4	NULL
to	NULL
+52	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Strong	NULL
complexes	NULL
were	NULL
also	NULL
formed	NULL
on	NULL
the	NULL
region	NULL
from	NULL
+52	NULL
to	NULL
+93	NULL
,	NULL
which	NULL
is	NULL
GC-rich	NULL
.	NULL

These	NULL
complexes	NULL
were	NULL
partially	NULL
competed	NULL
off	NULL
with	NULL
the	NULL
nonradioactive	NULL
probe	NULL
covering	NULL
the	NULL
same	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

The	NULL
region	NULL
from	NULL
-4	NULL
to	NULL
+93	NULL
has	NULL
several	NULL
Spl	NULL
and	NULL
NFL	NULL
sites	NULL
;	NULL
however	NULL
,	NULL
neither	NULL
the	NULL
Spl	NULL
nor	NULL
the	NULL
NFL	NULL
antibodies	NULL
caused	NULL
supershift	NULL
of	NULL
the	NULL
complexes	NULL
.	NULL

Although	NULL
the	NULL
anti-Sp2	NULL
antibody	NULL
induced	NULL
a	NULL
slight	NULL
supershift	NULL
,	NULL
the	NULL
anti-Sp3	NULL
antibody	NULL
had	NULL
the	NULL
strongest	NULL
effect	NULL
,	NULL
causing	NULL
the	NULL
complete	NULL
disappearance	NULL
of	NULL
complex	NULL
II	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
data	NULL
suggest	NULL
that	NULL
Sp3	NULL
is	NULL
one	NULL
of	NULL
the	NULL
main	NULL
factors	NULL
involved	NULL
in	NULL
complex	NULL
formation	NULL
in	NULL
this	NULL
region	NULL
;	NULL
other	NULL
members	NULL
of	NULL
the	NULL
Spl	NULL
family	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
protein-DNA	NULL
interaction	NULL
on	NULL
this	NULL
region	NULL
of	NULL
the	NULL
MAT2B	NULL
promoter	NULL
.	NULL

Chromatin	NULL
immunoprecipitation	NULL
studies	NULL
showed	NULL
that	NULL
both	NULL
the	NULL
anti-Spl	NULL
and	NULL
anti-Sp3	NULL
antibodies	NULL
were	NULL
independently	NULL
able	NULL
to	NULL
pull	NULL
down	NULL
the	NULL
MAT2B	NULL
promoter	NULL
,	NULL
because	NULL
PCR	NULL
products	NULL
were	NULL
obtained	NULL
in	NULL
reactions	NULL
with	NULL
primers	NULL
covering	NULL
the	NULL
regions	NULL
from	NULL
-174	NULL
to	NULL
-4	NULL
and	NULL
-4	NULL
to	NULL
+52	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
even	NULL
though	NULL
Sp3	NULL
seems	NULL
to	NULL
be	NULL
a	NULL
major	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
proximal	NULL
MAT2B	NULL
promoter	NULL
,	NULL
the	NULL
24923	NULL
TATA	NULL
TSSq	NULL
Sp	NULL
!	NULL

-	NULL
+	NULL
115	NULL
——I-—-l—I-—r32	NULL
-z	NULL
52	NULL
Spl	NULL
Sp1	NULL
+9	NULL
423	NULL
+52	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
Percentage	NULL
of	NULL
MAT2B	NULL
(	NULL
-115	NULL
)	NULL
pGL3-MaT2B	NULL
“	NULL
HE	NULL
pGL3-MAT2B	NULL
(	NULL
Mu	NULL
+9/+15	NULL
)	NULL
@	NULL
>	NULL
pGL3-MAT2B	NULL
(	NULL
Mu	NULL
+23/+28	NULL
)	NULL
{	NULL
E	NULL
>	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
125	NULL
Percentage	NULL
of	NULL
MAT2B	NULL
(	NULL
-4	NULL
)	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Effect	NULL
of	NULL
mutating	NULL
specific	NULL
factor	NULL
recognition	NULL
sites	NULL
on	NULL
MAT2B	NULL
promoter	NULL
on	NULL
in	NULL
vivo	NULL
activity	NULL
.	NULL

The	NULL
position	NULL
of	NULL
each	NULL
mutation	NULL
is	NULL
indicated	NULL
in	NULL
the	NULL
line	NULL
diagram	NULL
.	NULL

The	NULL
reporter	NULL
pGL8-MAT2B	NULL
(	NULL
-115	NULL
)	NULL
-Lue	NULL
or	NULL
constructs	NULL
with	NULL
and	NULL
without	NULL
TATA	NULL
and/or	NULL
Spl	NULL
mutations	NULL
were	NULL
transfected	NULL
into	NULL
Cos-1	NULL
cells	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Fig	NULL
.	NULL

4	NULL
legend	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
indicated	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
Mx	NULL
)	NULL
constructs	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
respective	NULL
wild-type	NULL
construct	NULL
activity	NULL
.	NULL

The	NULL
data	NULL
are	NULL
from	NULL
at	NULL
least	NULL
three	NULL
experiments	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

binding	NULL
of	NULL
Spl	NULL
to	NULL
this	NULL
site	NULL
im	NULL
vivo	NULL
can	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
.	NULL

Effect	NULL
of	NULL
Mutating	NULL
Specific	NULL
Sites	NULL
in	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
on	NULL
the	NULL
in	NULL
Vitro	NULL
Promoter	NULL
Activity-Several	NULL
mutations	NULL
were	NULL
also	NULL
made	NULL
to	NULL
probes	NULL
covering	NULL
the	NULL
region	NULL
from	NULL
-115	NULL
to	NULL
+93	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
position	NULL
+9	NULL
completely	NULL
abolished	NULL
protein-DNA	NULL
complex	NULL
formation	NULL
on	NULL
probes	NULL
representing	NULL
sequences	NULL
from	NULL
-115	NULL
to	NULL
+52	NULL
or	NULL
from	NULL
-4	NULL
to	NULL
+52	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
mutation	NULL
of	NULL
other	NULL
Spl	NULL
sites	NULL
in	NULL
the	NULL
region	NULL
from	NULL
-115	NULL
to	NULL
+52	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
complex	NULL
formation	NULL
.	NULL

Similarly	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
three	NULL
TBF	NULL
sites	NULL
located	NULL
between	NULL
-115	NULL
and	NULL
-4	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
complex	NULL
formation	NULL
.	NULL

Together	NULL
the	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9	NULL
is	NULL
key	NULL
for	NULL
protein-DNA	NULL
interaction	NULL
on	NULL
this	NULL
region	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

The	NULL
sequence	NULL
from	NULL
+52	NULL
to	NULL
+93	NULL
is	NULL
too	NULL
heavily	NULL
GC-rich	NULL
to	NULL
mutate	NULL
in	NULL
a	NULL
meaningful	NULL
way	NULL
.	NULL

Effect	NULL
of	NULL
Mutating	NULL
Specific	NULL
Sites	NULL
in	NULL
the	NULL
MAT2B	NULL
Promoter	NULL
on	NULL
the	NULL
in	NULL
Vivo	NULL
Promoter	NULL
Activity-The	NULL
effect	NULL
of	NULL
mutating	NULL
several	NULL
putative	NULL
factor	NULL
recognition	NULL
sites	NULL
located	NULL
in	NULL
the	NULL
region	NULL
between	NULL
-115	NULL
and	NULL
+52	NULL
on	NULL
the	NULL
in	NULL
vivo	NULL
activity	NULL
of	NULL
the	NULL
MAT2B	NULL
promoter	NULL
was	NULL
tested	NULL
;	NULL
however	NULL
,	NULL
only	NULL
two	NULL
mutations	NULL
affected	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

The	NULL
TATA	NULL
at	NULL
-32	NULL
and	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9	NULL
were	NULL
individually	NULL
or	NULL
simultaneously	NULL
mutated	NULL
on	NULL
the	NULL
pGL3-MAT2B	NULL
(	NULL
-115	NULL
)	NULL
-Lue	NULL
or	NULL
pGL3-MAT2B	NULL
(	NULL
-4	NULL
)	NULL
-Lue	NULL
reporter	NULL
construct	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
position	NULL
+9	NULL
reduced	NULL
promoter	NULL
activity	NULL
by	NULL
35-50	NULL
%	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
other	NULL
Spl	NULL
sites	NULL
located	NULL
in	NULL
the	NULL
region	NULL
from	NULL
-115	NULL
to	NULL
+52	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
activity	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
TATA	NULL
at	NULL
-32	NULL
reduced	NULL
in	NULL
vivo	NULL
activity	NULL
of	NULL
the	NULL
MAT2B	NULL
promoter	NULL
by	NULL
only	NULL
25	NULL
%	NULL
.	NULL

However	NULL
,	NULL
when	NULL
both	NULL
the	NULL
TATA	NULL
at	NULL
-382	NULL
and	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9	NULL
were	NULL
mutated	NULL
simultaneously	NULL
,	NULL
promoter	NULL
activity	NULL
was	NULL
reduced	NULL
by	NULL
almost	NULL
60	NULL
%	NULL
,	NULL
reach	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
24924	NULL
ing	NULL
a	NULL
level	NULL
that	NULL
is	NULL
comparable	NULL
with	NULL
that	NULL
driven	NULL
by	NULL
the	NULL
GC-rich	NULL
sequence	NULL
from	NULL
+52	NULL
to	NULL
+93	NULL
.	NULL

Together	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
GC-rich	NULL
sequences	NULL
in	NULL
the	NULL
region	NULL
from	NULL
+52	NULL
to	NULL
+93	NULL
can	NULL
drive	NULL
MAT2B	NULL
gene	NULL
expression	NULL
up	NULL
to	NULL
25-30	NULL
%	NULL
of	NULL
it	NULL
full	NULL
activity	NULL
,	NULL
whereas	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Spl	NULL
site	NULL
at	NULL
+9/+15	NULL
and	NULL
the	NULL
TATA	NULL
sequence	NULL
at	NULL
-32/-28	NULL
are	NULL
required	NULL
for	NULL
100	NULL
%	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
The	NULL
MAT	NULL
II	NULL
isozyme	NULL
is	NULL
expressed	NULL
in	NULL
all	NULL
tissues	NULL
in	NULL
which	NULL
it	NULL
is	NULL
found	NULL
as	NULL
an	NULL
oligomer	NULL
that	NULL
comprises	NULL
catalytic	NULL
«	NULL
2	NULL
(	NULL
53	NULL
kDa	NULL
)	NULL
and	NULL
a2	NULL
'	NULL
(	NULL
51	NULL
kDa	NULL
)	NULL
subunits	NULL
complexed	NULL
with	NULL
the	NULL
B	NULL
regulatory	NULL
subunit	NULL
(	NULL
38	NULL
kDa	NULL
)	NULL
(	NULL
15	NULL
,	NULL
22	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
B	NULL
subunit	NULL
lowers	NULL
the	NULL
K	NULL
,	NULL
,	NULL
,	NULL
value	NULL
of	NULL
the	NULL
enzyme	NULL
for	NULL
1-Met	NULL
and	NULL
confers	NULL
susceptibility	NULL
to	NULL
product	NULL
inhibition	NULL
by	NULL
AdoMet	NULL
(	NULL
26	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
have	NULL
not	NULL
been	NULL
able	NULL
to	NULL
detect	NULL
the	NULL
B	NULL
protein	NULL
in	NULL
E.	NULL
coli	NULL
or	NULL
yeast	NULL
extracts	NULL
(	NULL
26	NULL
,	NULL
35	NULL
)	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
high	NULL
level	NULL
of	NULL
homology	NULL
between	NULL
this	NULL
protein	NULL
and	NULL
enzymes	NULL
that	NULL
catalyze	NULL
the	NULL
reduction	NULL
of	NULL
thiamine	NULL
diphos-phate-linked	NULL
sugars	NULL
in	NULL
bacteria	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
unique	NULL
role	NULL
and	NULL
significance	NULL
of	NULL
the	NULL
protein	NULL
in	NULL
mammalian	NULL
cells	NULL
represents	NULL
an	NULL
intriguing	NULL
area	NULL
of	NULL
study	NULL
,	NULL
particularly	NULL
because	NULL
$	NULL
is	NULL
differen-tially	NULL
expressed	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
T	NULL
cells	NULL
and	NULL
subsequently	NULL
affects	NULL
AdoMet	NULL
levels	NULL
.	NULL

In	NULL
leukemic	NULL
T	NULL
cells	NULL
,	NULL
both	NULL
the	NULL
«	NULL
2	NULL
and	NULL
subunits	NULL
of	NULL
MAT	NULL
II	NULL
are	NULL
constitutively	NULL
expressed	NULL
at	NULL
a	NULL
high	NULL
level	NULL
.	NULL

Nonphysiological	NULL
polyclonal	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
primary	NULL
human	NULL
lymphocytes	NULL
induces	NULL
an	NULL
increased	NULL
expression	NULL
of	NULL
MAT	NULL
II	NULL
«	NULL
2	NULL
subunit	NULL
only	NULL
,	NULL
whereas	NULL
physiological	NULL
stimulation	NULL
via	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
results	NULL
in	NULL
a	NULL
down-regulation	NULL
of	NULL
the	NULL
B	NULL
subunit	NULL
(	NULL
25	NULL
)	NULL
.	NULL

This	NULL
is	NULL
accompanied	NULL
by	NULL
a	NULL
6-10-fold	NULL
increase	NULL
in	NULL
AdoMet	NULL
levels	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Thus	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
MAT2B	NULL
gene	NULL
may	NULL
be	NULL
an	NULL
important	NULL
mechanism	NULL
for	NULL
regulating	NULL
intracellular	NULL
levels	NULL
of	NULL
AdoMet	NULL
.	NULL

To	NULL
shed	NULL
light	NULL
on	NULL
the	NULL
mechanisms	NULL
underlying	NULL
the	NULL
differences	NULL
in	NULL
MAT	NULL
II	NULL
6	NULL
subunit	NULL
expression	NULL
in	NULL
different	NULL
cells	NULL
,	NULL
we	NULL
cloned	NULL
and	NULL
characterized	NULL
the	NULL
MAT2B	NULL
gene	NULL
and	NULL
its	NULL
5'-flanking	NULL
sequence	NULL
.	NULL

Promoter	NULL
activity	NULL
was	NULL
very	NULL
similar	NULL
in	NULL
Cos-1	NULL
cells	NULL
and	NULL
Jurkat	NULL
human	NULL
leukemic	NULL
cells	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
our	NULL
previous	NULL
observations	NULL
that	NULL
the	NULL
B	NULL
subunit	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
both	NULL
cell	NULL
types	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Minimal	NULL
promoter	NULL
activity	NULL
is	NULL
contained	NULL
between	NULL
position	NULL
+52	NULL
and	NULL
+93	NULL
,	NULL
which	NULL
is	NULL
rich	NULL
in	NULL
GC	NULL
content	NULL
.	NULL

However	NULL
,	NULL
full	NULL
promoter	NULL
activity	NULL
was	NULL
achieved	NULL
when	NULL
sequences	NULL
from	NULL
-115	NULL
to	NULL
+52	NULL
were	NULL
included	NULL
.	NULL

The	NULL
Spl	NULL
site	NULL
located	NULL
within	NULL
the	NULL
5'-noncoding	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
(	NULL
+9/+15	NULL
)	NULL
seems	NULL
to	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
this	NULL
enhancement	NULL
inasmuch	NULL
as	NULL
mutation	NULL
of	NULL
this	NULL
site	NULL
abolished	NULL
DNA-protein	NULL
interactions	NULL
and	NULL
significantly	NULL
reduced	NULL
promoter	NULL
activity	NULL
in	NULL
vivo	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
GC-rich	NULL
region	NULL
of	NULL
the	NULL
proximal	NULL
promoter	NULL
drives	NULL
the	NULL
residual	NULL
activity	NULL
when	NULL
this	NULL
Spl	NULL
site	NULL
is	NULL
mutated	NULL
.	NULL

Further	NULL
enhancement	NULL
of	NULL
MAT2B	NULL
promoter	NULL
activity	NULL
is	NULL
conferred	NULL
by	NULL
the	NULL
TATA	NULL
at	NULL
-32/-28	NULL
.	NULL

When	NULL
the	NULL
Spl	NULL
at	NULL
+9	NULL
and	NULL
the	NULL
TATA	NULL
at	NULL
-32	NULL
are	NULL
mutated	NULL
simultaneously	NULL
,	NULL
promoter	NULL
activity	NULL
is	NULL
reduced	NULL
by	NULL
60-70	NULL
%	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
Sp3	NULL
seems	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
Sp1	NULL
site	NULL
at	NULL
+9/+15	NULL
,	NULL
although	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
that	NULL
Spl	NULL
and	NULL
Sp2	NULL
are	NULL
also	NULL
part	NULL
of	NULL
the	NULL
complexes	NULL
that	NULL
form	NULL
on	NULL
this	NULL
site	NULL
.	NULL

That	NULL
Sp3	NULL
is	NULL
involved	NULL
in	NULL
regulating	NULL
MAT2B	NULL
promoter	NULL
activity	NULL
is	NULL
particularly	NULL
interesting	NULL
in	NULL
light	NULL
of	NULL
our	NULL
recent	NULL
studies	NULL
that	NULL
showed	NULL
that	NULL
this	NULL
transcription	NULL
factor	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
MAT2A	NULL
gene	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
the	NULL
same	NULL
enzyme	NULL
.	NULL

As	NULL
mentioned	NULL
above	NULL
,	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
a	NULL
physiological	NULL
stimulus	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
«	NULL
2	NULL
and	NULL
down-regulates	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
B	NULL
subunit	NULL
,	NULL
whereas	NULL
in	NULL
leukemic	NULL
T	NULL
cells	NULL
both	NULL
subunits	NULL
are	NULL
expressed	NULL
at	NULL
a	NULL
high	NULL
level	NULL
(	NULL
22	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Sp3	NULL
is	NULL
a	NULL
bifunc-tional	NULL
protein	NULL
that	NULL
can	NULL
both	NULL
activate	NULL
and	NULL
repress	NULL
the	NULL
transcription	NULL
of	NULL
genes	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Internal	NULL
isoforms	NULL
of	NULL
this	NULL
protein	NULL
containing	NULL
activation	NULL
and/or	NULL
repressor	NULL
domains	NULL
have	NULL
been	NULL
described	NULL
(	NULL
40	NULL
)	NULL
.	NULL

It	NULL
is	NULL
conceivable	NULL
that	NULL
Sp3	NULL
may	NULL
enhance	NULL
MAT2A	NULL
and	NULL
The	NULL
Human	NULL
MAT2B	NULL
Gene	NULL
and	NULL
Its	NULL
Promoter	NULL
MAT2B	NULL
gene	NULL
expression	NULL
in	NULL
leukemic	NULL
T	NULL
cells	NULL
while	NULL
enhancing	NULL
MAT2A	NULL
and	NULL
suppressing	NULL
MAT2B	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
role	NULL
of	NULL
the	NULL
Spl	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
regulating	NULL
MAT	NULL
II	NULL
«	NULL
2	NULL
and	NULL
B	NULL
subunit	NULL
expression	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
T	NULL
cells	NULL
are	NULL
ongoing	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
an	NULL
Spl	NULL
site	NULL
on	NULL
the	NULL
promoter	NULL
for	NULL
both	NULL
subunits	NULL
that	NULL
is	NULL
key	NULL
for	NULL
driving	NULL
promoter	NULL
activity	NULL
puts	NULL
us	NULL
closer	NULL
to	NULL
our	NULL
goal	NULL
to	NULL
elucidate	NULL
the	NULL
differential	NULL
regulation	NULL
of	NULL
MAT	NULL
II	NULL
subunits	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
T	NULL
cells	NULL
.	NULL

Achieving	NULL
this	NULL
goal	NULL
will	NULL
allow	NULL
us	NULL
to	NULL
design	NULL
targeted	NULL
therapeutic	NULL
strategies	NULL
for	NULL
potentiating	NULL
intracellular	NULL
AdoMet	NULL
levels	NULL
that	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
control	NULL
of	NULL
malignant	NULL
growth	NULL
.	NULL

REFERENCES	NULL
.	NULL

Cantoni	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1953	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

204	NULL
,	NULL
403-416	NULL
2	NULL
.	NULL

Mudd	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1973	NULL
)	NULL
The	NULL
Adenosyltransferases	NULL
:	NULL
The	NULL
Enzymes	NULL
,	NULL
Group	NULL
Transfer	NULL
(	NULL
Part	NULL
A	NULL
)	NULL
(	NULL
Bayer	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
ed	NULL
)	NULL
3rd	NULL
Ed	NULL
.	NULL

,	NULL
pp	NULL
.	NULL

121-154	NULL
,	NULL
Academic	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
3	NULL
.	NULL

Finkelstein	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Kyle	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Martin	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Pick	NULL
,	NULL
A.	NULL
M.	NULL
(	NULL
1975	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

66	NULL
,	NULL
81-87	NULL
4	NULL
.	NULL

Tabor	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Tabor	NULL
,	NULL
H.	NULL
(	NULL
1984	NULL
)	NULL
Adv	NULL
.	NULL

Enzymol	NULL
.	NULL

Relat	NULL
.	NULL

Areas	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

56	NULL
,	NULL
251-282	NULL
5	NULL
.	NULL

Mudd	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Levy	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Skovby	NULL
,	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
Disorders	NULL
of	NULL
Transsulfuration	NULL
:	NULL
The	NULL
Molecular	NULL
and	NULL
Metabolic	NULL
Basis	NULL
of	NULL
Inherited	NULL
Diseases	NULL
(	NULL
Scriver	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Beaudet	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Sly	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
Valle	NULL
,	NULL
D.	NULL
,	NULL
eds	NULL
)	NULL
7th	NULL
Ed	NULL
.	NULL

,	NULL
McGraw-Hill	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
6	NULL
.	NULL

Kotb	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

59	NULL
,	NULL
125-143	NULL
7	NULL
.	NULL

Hoffman	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

94	NULL
,	NULL
228-228	NULL
8	NULL
.	NULL

Mato	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Alvarez	NULL
,	NULL
L.	NULL
,	NULL
Ortiz	NULL
,	NULL
P.	NULL
,	NULL
Mingorance	NULL
,	NULL
J.	NULL
,	NULL
Duran	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Pajares	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Adv	NULL
.	NULL

Exp	NULL
.	NULL

Med	NULL
.	NULL

Biol	NULL
.	NULL

368	NULL
,	NULL
118-117	NULL
9	NULL
.	NULL

Okada	NULL
,	NULL
G.	NULL
,	NULL
Teraoka	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Tsukada	NULL
,	NULL
K.	NULL
(	NULL
1981	NULL
)	NULL
Biochemistry	NULL
20	NULL
,	NULL
934-940	NULL
10	NULL
.	NULL

Kotb	NULL
,	NULL
M.	NULL
,	NULL
Mudd	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Mato	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Kredich	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
Chou	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
and	NULL
Cantoni	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

18	NULL
,	NULL
51-52	NULL
11	NULL
.	NULL

Suma	NULL
,	NULL
Y.	NULL
,	NULL
Shimizu	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Tsukada	NULL
,	NULL
K.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Biockem	NULL
.	NULL

(	NULL
Tokyo	NULL
)	NULL
100	NULL
,	NULL
67-75	NULL
12	NULL
.	NULL

Pajares	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Corrales	NULL
,	NULL
F.	NULL
,	NULL
Duran	NULL
,	NULL
C.	NULL
,	NULL
Mato	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Alvarez	NULL
,	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

309	NULL
,	NULL
1-4	NULL
13	NULL
.	NULL

Mingorance	NULL
,	NULL
J.	NULL
,	NULL
Alvarez	NULL
,	NULL
L.	NULL
,	NULL
Pajares	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Mato	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Int	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

29	NULL
,	NULL
485-491	NULL
14	NULL
.	NULL

Oden	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Clarke	NULL
,	NULL
S.	NULL
(	NULL
1983	NULL
)	NULL
Biochemistry	NULL
22	NULL
,	NULL
2978-2986	NULL
15	NULL
.	NULL

Kotb	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kredich	NULL
,	NULL
N.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260	NULL
,	NULL
3923-3930	NULL
16	NULL
.	NULL

Langkamp-Henken	NULL
,	NULL
B.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Jr.	NULL
,	NULL
Price	NULL
,	NULL
J.	NULL
O.	NULL
,	NULL
De	NULL
La	NULL
Rosa	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1201	NULL
,	NULL
397-404	NULL
17	NULL
.	NULL

Liau	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Chang	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
Belanger	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Grenier	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

89	NULL
,	NULL
162-169	NULL
18	NULL
.	NULL

Sullivan	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Hoffman	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
Biochemistry	NULL
22	NULL
,	NULL
1636-1641	NULL
19	NULL
.	NULL

Mitsui	NULL
,	NULL
K.	NULL
,	NULL
Teraoka	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Tsukada	NULL
,	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
11211-11216	NULL
20	NULL
.	NULL

Horikawa	NULL
,	NULL
S.	NULL
,	NULL
Sasuga	NULL
,	NULL
J.	NULL
,	NULL
Shimizu	NULL
,	NULL
K.	NULL
,	NULL
Ozasa	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Tsukada	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
13683-13686	NULL
21	NULL
.	NULL

Gil	NULL
,	NULL
B.	NULL
,	NULL
Casado	NULL
,	NULL
M.	NULL
,	NULL
Pajares	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Bosca	NULL
,	NULL
L.	NULL
,	NULL
Mato	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Martin-Sanz	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
.	NULL

Alvarez	NULL
,	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
Hepatology	NULL
24	NULL
,	NULL
876-881	NULL
22	NULL
.	NULL

De	NULL
La	NULL
Rosa	NULL
,	NULL
J.	NULL
,	NULL
LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Jr.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Koth	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
10699-10704	NULL
23	NULL
.	NULL

Kotb	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kredich	NULL
,	NULL
N.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1089	NULL
,	NULL
253-260	NULL
24	NULL
.	NULL

De	NULL
La	NULL
Rosa	NULL
,	NULL
J.	NULL
,	NULL
Ostrowski	NULL
,	NULL
J.	NULL
,	NULL
Hryniewicz	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Kredich	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
Kotb	NULL
,	NULL
M.	NULL
,	NULL
LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Jr.	NULL
,	NULL
Valentine	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
21860-21868	NULL
25	NULL
.	NULL

LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Jr.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
16040-16047	NULL
26	NULL
.	NULL

Halim	NULL
,	NULL
A-B	NULL
.	NULL

,	NULL
LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274	NULL
,	NULL
29720-29725	NULL
27	NULL
.	NULL

Halim	NULL
,	NULL
A.-B	NULL
.	NULL

,	NULL
LeGros	NULL
,	NULL
L.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
2001	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

276	NULL
,	NULL
9784-9791	NULL
28	NULL
.	NULL

Hiroki	NULL
,	NULL
T.	NULL
,	NULL
Horikawa	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Tsukada	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

250	NULL
,	NULL
653-660	NULL
29	NULL
.	NULL

Sakata	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Shelly	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
Ruppert	NULL
,	NULL
S.	NULL
,	NULL
Schutz	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Chou	NULL
,	NULL
J.	NULL
Y	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
13978-13986	NULL
30	NULL
.	NULL

Ubagai	NULL
,	NULL
T.	NULL
,	NULL
Lei	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Huang	NULL
,	NULL
S.	NULL
,	NULL
Mudd	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Levy	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Chou	NULL
,	NULL
J.	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96	NULL
,	NULL
1948-1947	NULL
31	NULL
.	NULL

LeGros	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Halim	NULL
,	NULL
A.-B	NULL
.	NULL

,	NULL
Geller	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
2000	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

275	NULL
,	NULL
2359-2366	NULL
32	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Hwang	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Junn	NULL
,	NULL
E.	NULL
,	NULL
Lee	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Mouradian	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
2000	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

275	NULL
,	NULL
88863-38869	NULL
33	NULL
.	NULL

Wang	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Wilkinson	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
2000	NULL
)	NULL
BioTechniques	NULL
29	NULL
,	NULL
976-978	NULL
34	NULL
.	NULL

Breathnach	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1981	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

50	NULL
,	NULL
849-383	NULL
35	NULL
.	NULL

Kotb	NULL
,	NULL
M.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Markham	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Kredich	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
De	NULL
La	NULL
Rosa	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Beachey	NULL
,	NULL
E.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1040	NULL
,	NULL
137-144	NULL
36	NULL
.	NULL

Pissowotzki	NULL
,	NULL
K.	NULL
,	NULL
Mansouri	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Piepersberg	NULL
,	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Gen.	NULL
Genet	NULL
.	NULL

231	NULL
,	NULL
113-123	NULL
37	NULL
.	NULL

De	NULL
La	NULL
Rosa	NULL
,	NULL
J.	NULL
,	NULL
Geller	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Le	NULL
Gros	NULL
,	NULL
H.	NULL
L.	NULL
J.	NULL
,	NULL
and	NULL
Kotb	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

52	NULL
,	NULL
3361-3366	NULL
38	NULL
.	NULL

Suske	NULL
,	NULL
G.	NULL
(	NULL
1999	NULL
)	NULL
Gene	NULL
288	NULL
,	NULL
291-300	NULL
39	NULL
.	NULL

Majello	NULL
,	NULL
B.	NULL
,	NULL
De	NULL
Luca	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Lania	NULL
,	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
4021-4026	NULL
40	NULL
.	NULL

Kennett	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Udvadia	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Horowitz	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

25	NULL
,	NULL
3110-3117	NULL
a	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Regulation	NULL
of	NULL
the	NULL
Human	NULL
MA	NULL
T2B	NULL
Gene	NULL
Encoding	NULL
the	NULL
Regulatory	NULL
B	NULL
Subunit	NULL
of	NULL
Methionine	NULL
AdenosylItransferase	NULL
,	NULL
MAT	NULL
II	NULL
Leighton	NULL
LeGros	NULL
,	NULL
Abdel-Baset	NULL
Halim	NULL
,	NULL
Margaret	NULL
E.	NULL
Chamberlin	NULL
,	NULL
Arthur	NULL
Geller	NULL
and	NULL
Malak	NULL
Kotb	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2001	NULL
,	NULL
276:24918-24924.	NULL
doi	NULL
:	NULL
10.1074/jbc.M102816200	NULL
originally	NULL
published	NULL
online	NULL
May	NULL
3	NULL
,	NULL
2001	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
doi	NULL
:	NULL
10.1074/jbe.M102816200	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
38	NULL
references	NULL
,	NULL
15	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

